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Executive summary
The format for this third report of the Lancet Commission 
follows the same pattern as in 2015 in concentrating on 
the main recommendations, all of which are evidence 
based and have been most carefully considered in terms 
of their ability to reduce the current burden of liver 
disease in the UK and its financial cost. The working 
groups set up around the recommendations have 
concentrated this year on producing a set of the main 
metrics, which will enable further charting of disease 
prevalence and consequences on an annual basis. They 
have also identified those areas where important data are 
not being obtained, which needs to be rectified. The 
metrics shown were decided on after extensive discussion 
and in many cases numerical data are incomplete, having 
not been available within the time frame for this report. 
Where targets have not been set, the aim is to consider 
these further in the next year’s programme of work.
The initial ten recommendations have been reduced 
from ten to eight because of some overlap between the 
original points. [A: we are not able to include panels, 
figures, or tables in the summary, so the panel has been 
converted to text here. I have copied the previous sentence 
into the introduction of the main text so that the panel 
can be included there.] The eight recommendations are: 
(1) improving expertise and facilities in primary care to 
strengthen detection of early disease and its treatment, 
and screening of high-risk patients in the community; (2) 
establishment of acute liver services in district general 
hospitals linked with 30 regional specialist centres for 
complex investigations and treatment, and increased 
provision of medical and nursing training in hepatology; 
(3) a national review of liver transplantation to ensure 
better access for patients to increase capacity; (4) specialist 
paediatric services and continuity of care in transition 
arrangements for children with liver disease reaching 
adult life; (5) measures to reduce overall alcohol 
consumption in the country; (6) promotion of healthy 
lifestyles to reduce obesity and the burden of non-alcoholic 
fatty liver disease; (7) eradication of chronic hepatitis C 
virus infection from the UK [A: correct?] by 2030 and a 
major reduction in the burden of disease for hepatitis B; 
and (8) increasing awareness of liver disease in the 
general population and within the National Health 
Service (NHS), including the work of liver patient support 
groups.
The recommendations are in agreement with the 
ongoing thinking and action of the All Party 
Parliamentary Group on Liver Health, with which we are 
increasingly liaising. The target audience of this report, 
as for the previous reports, encompasses all those 
involved in health care, including hospital consultants, 
general practitioners, public health physicians, and most 
importantly, those involved in industry and marketing. 
The recently published, comprehensive Global Burden of 
Disease Study 2015 also includes important data on 
disease burden for alcohol, obesity, and viral hepatitis in 
relation to other major non-communicable diseases 
related to lifestyle issues, including smoking.
For many of the recommendations the metrics show 
little progress in terms of reduced disease burden, 
although together with the efforts of other bodies and 
agencies, there has been some movement in that 
direction. Thus, for recommendation 1, the recently 
published guidelines by NICE on fatty liver disease and 
the diagnosis of cirrhosis are likely to help considerably 
in improving clinical management at general practitioner 
and community level, giving guidance as they do on the 
best pathways to follow for the early identification 
and treatment of liver disease. Similarly, for 
recommendation 2, on the need to improve hospital 
services, we can point to the completion of a major 
review of hospital staffing and facilities for the care of the 
sick liver patient in hospital. These will inform further 
efforts to improve hepatological expertise and facilities 
within district general hospitals and the desired networks 
with specialist centres.
The updated version of the maps published in last 
year’s report illustrate the considerable variation in levels 
of current provision and will be of value in discussions 
on rationalisation and avoidance of duplication in 
provision of acute services being proposed. [A: it’s not 
possible to include figures in the summary, but the maps 
are cited and included later in the main text] The maps 
also illustrate the need for greater provision of liver 
services in the deprived areas that have the highest rates 
of liver disease morbidity and mortality. The number of 
district general hospitals that do not meet the criteria for 
an acute liver service is unacceptable.
Recommendation 3, relating to the national strategic 
review of liver transplantation in the UK, is proceeding, 
albeit rather slowly. This is because of the need, with the 
financial constraints facing the NHS at present, for the 
costs of this procedure to be properly considered along 
with agreement on work packages. The recommendation 
remains that additional centres are set up to correct the 
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present geographical inequalities and increase the 
number of liver transplants carried out. Of note here 
during the past year is the likely increase in the number 
of donor organs available as a result of new developments 
in organ perfusion which can return function to donor 
livers, particularly those obtained from donors after 
cardiac death that were previously considered too 
damaged for use. Furthermore, initial results of the 
introduction of presumed consent in Wales have shown 
a striking increase in the number of organs being 
donated over the first four months of its operation.
Recommendation 4 highlights again the ever 
increasing population of adolescents with liver disease 
requiring supervision and care arising from the better 
results of treatment of infants and children including the 
use of liver transplantation. The measures needed are 
outlined with some encouraging pilot statistics.
Sadly the sections about recommendations, 5, 6, and 7, 
on the consequences of the lifestyle issues of excess 
alcohol consumption and obesity, as well as viral 
hepatitis, make depressing reading. The section on liver 
disease due to alcohol shows the increase in alcohol 
consumption and hospital admissions that was predicted 
to follow removal of the escalator tax in 2014. The 
necessary measures to reverse this are again set out in 
this section including further information on the value 
of the minimum unit pricing policy [A: have I 
spelled out “MUP” correctly?]. A recently published, 
nationally commissioned representative survey of over 
3000 respondents in Northern Ireland [A: as we cannot 
include references in the summary, the citation has been 
removed here and subsequent references renumbered.] 
again showed that the minimum unit pricing [A: ok?] 
policy targeted those suffering the greatest harm from 
drinking and would significantly reduce alcohol 
attributable mortality. Recent studies have also shown 
that the percentage of total alcohol consumed by the 
heavy drinkers has increased from 13% to 17%.
Similarly there is little encouragement to report for 
recommendation 6, on the introduction of effective 
measures to reduce obesity rates for the 60% of the 
population who are now in the overweight category. The 
outcry from the medical profession and public alike on the 
watering down of the sugar tax proposal is some indication 
of the realisation of the harmful effects of obesity in 
causing diabetes, heart attacks, and liver disease. 
Surveillance programmes for primary hepatocellular 
carcinoma in patients with cirrhosis as well as those with 
fatty liver disease are still not being implemented in 
district general hospitals despite the continued increase in 
the number of such cases. The enormous cost of obesity to 
patient health, to the NHS, and to society in general, are 
highlighted. In the context of hepatocellular carcinoma 
development, smoking, it should be emphasised, remains 
an important contributing but preventable risk factor.
Recommendation 7 does portray a more hopeful note 
on the treatment of patients with hepatitis C. The new 
drugs that have been introduced are proving in practice 
to be both efficacious and safe, with resulting high levels 
of viral clearance. On present evidence, the risk of 
selecting resistant mutations would appear to be low. 
Operational Delivery Networks are in place throughout 
England and the main issues relate to how many and 
which cases should be treated, with the limitation on 
total cost imposed by NHS England. The very high price 
of the medication imposed by manufacturers on high 
income countries remains difficult to justify.
For recommendation 8, which relates to increasing 
public awareness of health problems from liver disease, 
there is undoubtedly very much more activity in the 
media on lifestyle health-care issues. Most importantly, 
the Commission is able to report considerable ongoing 
success in meeting with Members of Parliament (MPs). 
Engaging their support is essential if the necessary 
legislation and regulation are to be finally approved by 
Parliament. National liver disease profiles detailing 
disease prevalence and mortality have been produced for 
each of the 533 parliamentary constituencies and show a 
17-fold difference in the rates for the most deprived areas. 
[A: please clarify; do you mean a 17-fold difference in 
rates between the most and least deprived areas?]
Introduction 
Are we being too optimistic in seeing a little light at the 
end of the tunnel for the efforts of the Lancet Commission 
to reduce levels of morbidity and mortality from liver 
disease in the UK, which predominantly affects those 
still in working life and is increasingly being seen in the 
young? Lifestyle issues of excess alcohol consumption, 
obesity, and viral hepatitis, responsible for the majority 
of liver illness in this country, are increasingly being 
featured in the media. As yet, however, the long 
entrenched government policies on alcohol and obesity 
remain in place, and the lobbies of the food and drinks 
industry continue to have a major influence. The 
increasing demands on the National Health Service 
(NHS) and the resulting financial pressures must be a 
strong argument for the introduction of measures that 
can substantially reduce the prevalence of disease. The 
health and cost benefits to the country from tackling 
smoking through regulation and taxation should be an 
encouragement to Parliament to follow similar initiatives 
for the other major lifestyle issues. £2·1 billion is spent 
each year on the treatment of liver disease. Hospital 
admissions and mortality rates are increasing again, as 
described in this third report of the Lancet Commission. 
Being largely preventable, this cannot be justified; nor 
can the figure of nearly 60% of UK [A: correct?] police 
officers’ time being spent on alcohol-related offenses. 
Furthermore, according to HM Treasury’s figures, 
without the cuts and freezes in alcohol duty over the past 
few years, including those in the 2015 government 
budget, alcohol duty would have raised £770 million 
more for the government exchequer in 2016–17. As a 
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result of scrapping the duty escalator, government 
finances will be £2·9 billion worse off by 2017–18.1 
[A: references have been renumbered to accommodate 
citations added during peer review and deletion of first 
reference from summary] The costs of obesity alone 
amount to £5·1 bn a year for the NHS, with 40 000 deaths 
linked to people being overweight or obese. There were 
440 288 admissions to hospitals in England in 2014–15 in 
which obesity was the main or secondary reason for a 
person being admitted.
This Lancet follow-up report, with its emphasis on 
metrics, gives many other examples of the cost to the 
country of not taking the necessary measures over 
lifestyle issues. Sadly, plans for introduction of a sugar 
tax, proposed in the Queen’s Speech to Parliament, have 
been watered down, particularly with respect to important 
limits on advertising junk food, although proposals on 
sugary drinks remain. How effective will be the targets 
set on the food industry for reducing sugar content of 
foods? Sally Davies, Chief Medical Officer for England, 
has bravely reduced safe limits for alcohol consumption 
for both women and men, on the basis of national and 
international evidence of the progressive increased risk 
of developing various cancers, including the common 
ones of breast and colon.
On a more optimistic note, two guidelines for the 
investigation and management of liver disease published 
by the National Institute for Health and Care Excellence 
(NICE) and guidelines by the British Society of 
Gastroenterology should help in the earlier detection 
and management of liver disease. This year has also 
seen the appointment of Jez Thompson as the jointly 
funded British Liver Trust and Royal College of General 
Practitioners Clinical Champion of Liver Disease. 
Already he is making an impact, as will be evident in his 
contribution to this report [A: correct?]. Improving 
health care for patients with liver disease in district 
general hospitals is also of vital importance, as 
highlighted by the adverse reports by the National 
Confidential Enquiry into Patient Outcome and Death 
(NCEPOD) and the new data from a comprehensive 
national survey of staffing and hospital facilities. This [A: 
by ‘this’ do you mean the data/reports?] should provide 
the basis for better and more equitable planning of 
services, particularly in deprived areas with high 
incidence of liver disease. Public Health England (PHE) 
launched in August, 2016, a new tool to help local 
authorities prevent or reduce the impact of alcohol 
harm. Known as CLeaR, and based on the success of the 
tobacco control CLeaR tool, it provides a framework for 
local partnerships to review local structures and alcohol 
services. Additionally Scotland is moving forward again 
on introducing the minimum unit price for alcohol, and 
Wales and Northern Ireland are pursuing major 
programmes based on strong government support 
tackling the harms of liver disease. More information on 
the work going on in the devolved countries is considered 
in the relevant sections of this report and in the general 
reviews [A: which general reviews?].
Encouraging also this year, and following a start made 
in 2015, has been the successful and increasing dialogue 
with MPs on raising awareness of liver disease in 
Parliament. The work has been greatly helped by the 
involvement of a lobbying agency, Incisive Health, to 
whom we are indebted for their ability in making contacts 
and in following them through. [A: reference to Norgine 
has been deleted, as this information is usually restricted 
to the competing interests/acknowledgments section] 
Representatives of the Lancet Commission held 16 one-
to-one meetings with MPs from the government and 
opposition parties. The House of Lords had a debate on 
the implementation of the Lancet Commission’s 
!
BACKGROUND
Liver disease is the third most common 
cause of premature death in the UK and 
the national liver disease health 
outcomes are worse than in other 
western European countries.1
Over the last decade, the number of liver 
disease-related hospital admissions in 
England has increased by half,2 placing an 
ever greater strain on the health service.  
Liver disease disproportionally affects the 
poorest and the most vulnerable in society 
and is a major factor in generating socio-
economic health inequalities.3  
LIVER DISEASE IN 
ENGLAND 
 
201,724  
 YEARS OF WORKING LIFE 
were lost in England due to liver disease 
in 2012-14. 
That is more than the number of 
working years lost due to lung and 
colorectal cancers combined (two 
most common non-sex-specific 
cancers).6 
 
The liver disease 
MORTALITY RATE 
amongst under-75s in 
England is 
 17.8  
 
per 100,000 
 
 
 
282,299  
 
HOSPITAL 
ADMISSIONS 
due to liver and liver-related disease 
were recorded in England in  
2014-15.  
There is a five-fold variation in the 
number of admissions  
amongst parliamentary 
constituencies in  
England.8  
 
LIVER DISEASE RISK FACTORS IN 
ENGLAND 
!ALCOHOL
Alcohol is the most common cause  
of liver disease in England and the 
biggest risk factor for death in men 
younger than 60 years.1  
In England, it is estimated that 
26.75% of people over 16 years who 
drink alcohol engage in “increasing 
risk” or “higher risk” drinking.9 
 
 
OBESITY
Obesity is the key risk factor for  
non-alcoholic fatty liver disease 
(NAFLD).  
In England, 64.6% of adults are 
classified as overweight or obese.10 
 
33.6% of children in England 
between 10 and 11 years are 
estimated to have excess weight.11 
VIRAL HEPATITIS
The number of deaths due to viral  
hepatitis is increasing.1 The infection  
can lead to chronic liver disease and  
liver cancer. 
There are an estimated 214,000 
individuals chronically infected with 
hepatitis C in the UK.12 
Although the number of people with 
hepatitis B virus is unknown, the figure is 
probably similar to those with hepatitis C.1    
 
 26.75% 
INCREASING OR 
HIGHER RISK  
DRINKERS 
 
70.8% 
!OVERWEIGHT OR OBESE 
 
214,000 
!
HEPATITIS C 
INFECTIONS  
Foundation for Liver Research received an unrestricted educational grant from Norgine in support of this engagement programme. Norgine have no editorial control over this activity. 
NATIONAL  
LIVER DISEASE PROFILE 
 
LIVER DISEASE IN NUMBERS 
o Liver disease mortality rates in the UK 
increased 400% since 19701 
 
o £2.1billion per year spent on 
treating liver disease4  
 
o More than 1million admissions to 
hospital per year as a result of alcohol-
related disorders1 
 
o 62,000 years of working life lost to 
liver disease every year1 
 
 
o Care for patients who died of liver disease 
rated as less than good in  
more than half of cases5  
 
There is a nearly four-fold 
variation in under-75s liver 
disease mortality amongst local 
authority areas in England.7 
 
Liver disease
constitutes the
Third most common
Cause of premature
Death in the UK
Figure 1: National liver disease profile for England [A: figure title ok? Please add publisher and year of publication]
[A: please state copyright holder and confirm that you have obtained formal permission to use]
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recommendations and multiple parliamentary questions 
have been tabled in both the House of Commons and the 
House of Lords on topics related to liver  disease. In 
addition to private meetings, the Lancet Commission 
partnered with the All Party Parliamentary Group 
(APPG) on Liver Health in holding two parliamentary 
briefing events; one in the House of Lords (October, 
2015), and another in the House of Commons (July, 
2016). Both events sought to raise parliamentary 
awareness of the Lancet Commission’s blueprint for 
improvement and of the need to act to address the 
continuing liver disease crisis. Together these events 
were attended by 38 MPs. In addition, we have been 
liaising closely with the Children of Alcoholics APPG.
July, 2016, saw the launch of the Lancet Commission’s 
most recent campaigning resource, Constituency Liver 
Disease Profiles, designed to bring to life the health and 
financial impact of liver disease on local communities 
and generate greater interest in liver disease among 
MPs. As well as the national liver disease profiles 
(figure 1) [A: in several cases, figure citations appeared to 
give the wrong figure numbers. I have renumbered 
figures and citations accordingly - please check that the 
figures are in the correct order and that citations in the 
text are correct throughout. For all images derived from 
other publications, please ensure that the source and 
copyright holder are acknowledged in the figure legend 
and confirm that you have obtained permission to use 
the figure - I have flagged this up in individual figure 
legends where it’s clear that a figure has been published 
elsewhere, but I may have missed some] part of this 
initiative’s work has been to produce a customised 
infographic for each of the 533 parliamentary 
constituencies in England, bringing together exclusive 
data provided by Public Health England and existing data 
intelligence to provide a concise summary of the impact 
of liver disease on local populations. The data collected as 
part of this exercise have been used in targeting MPs 
from the 50 areas with the highest burden of liver 
disease. The remarkable 17-fold difference between the 
burden of liver disease in the North West of England and 
rates in the Home Counties [A: you cited ‘table 1’ here, 
but the text does not match any of the supplied tables, so 
I have deleted the citation] is a telling statistic and, with 
its association with social deprivation, shows also the 
need for wider social and public health measures in 
addition to reducing alcohol consumption and obesity.
The constituency liver disease profiles are publically 
accessible on the Foundation for Liver Research website2 
and available to the wider liver disease community to be 
used in the briefing of relevant political stakeholders on 
the burden of liver disease in their areas.
The Commission will continue its engagement with 
Parliament and will explore other ways to communicate 
the burden of liver disease to key stakeholders, such as 
healthcare commissioners, local authorities, and those 
charged with developing and implementing sustainability 
and transformation plans.
Panel 1 summarises the Commission’s recom 
mendations, which have been reduced from ten to eight 
in order to reduce overlap between the original points. 
[A: ok to include panel 1 here? (All figures, tables, and 
panels need to be cited in the text)]
Recommendation 1: improving expertise and 
facilities in primary care to strengthen detection 
of early disease and its treatment, and screening 
of high-risk patients in the community
[A: we cannot use bullet points within the main text, so 
the text has been edited accordingly The most common 
forms of liver disease have risk factors shared with other 
co-morbidities that are typically already under primary 
care surveillance, and which can be identified and 
addressed within primary care to prevent liver pathology 
developing. Once developed, liver disease is typically 
slow to progress, and the patient with early disease 
might remain asymptomatic for years, while the disease 
itself is slowly advancing in severity. Early intervention, 
risk modification and treatment within primary care 
might prevent or retard progression to cirrhosis and end 
Panel 1: Updated recommendations of the Lancet 
Standing Commission for Liver Disease in the UK 
[A: title ok?]
Recommendation 1: improving expertise and facilities in 
primary care to strengthen detection of early disease and its 
treatment, and screening of high-risk patients in the 
community
Recommendation 2: establishment of acute liver services in 
district general hospitals linked with 30 regional specialist 
centres for complex investigations and treatment, and 
increased provision of medical and nursing training in 
hepatology
Recommendation 3: a national review of liver transplantation 
to ensure better access for patients to increase capacity
Recommendation 4: specialist paediatric services and 
continuity of care in transition arrangements for children 
with liver disease reaching adult life
Recommendation 5: measures to reduce overall alcohol 
consumption in the country
Recommendation 6: promotion of healthy lifestyles to 
reduce obesity and the burden of non-alcoholic fatty liver 
disease
Recommendation 7: eradication of chronic hepatitis C virus 
infection from the country by 2030 and a major reduction in 
the burden of disease for hepatitis B
Recommendation 8: increasing awareness of liver disease in 
the general population and within the NHS; work of liver 
patient support groups.
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stage liver disease. Patients with advanced liver disease 
spend the majority of their lives within their own 
families and communities where they are registered 
with a general practitioner. Although many people with 
advanced liver disease attend secondary care outpatient 
clinics and some have repeated hospital admissions 
during acute crises, much of their health care is 
provided within community settings. For these reasons, 
clinicians working in primary care and other community 
services, including community drug services, have 
unique and important roles in the prevention, early 
detection and management of liver disease. Engagement 
will reflect local factors, including local prevalence, 
population demographics, and level of prioritisation by 
local commissioners, as well as mechanisms to 
incentivise staff and investment in support services.
Primary prevention of liver disease includes screening 
for hazardous and harmful alcohol use and obesity3 and 
having access to early in-house interventions or referral 
pathways to services to address these issues.4,5 Hepatitis 
B immunisation for those at risk, including injecting 
drug users, is another form of primary prevention. 
Critical to primary care, and to pressing workload 
considerations, is the recognition that many risk factors 
for liver disease are also risk factors for other long-term 
conditions. Effective screening for liver disease risk 
factors does not necessarily mean new work, but rather 
the linking of liver disease to current best practice and 
the monitoring and management of other conditions.
Secondary prevention of liver disease includes screening 
for hepatitis C6,7 and hepatitis B infections in those who 
have been, or are current, drug injectors or who have 
other risk factors,8 and onward referral if necessary.4 It also 
includes case-finding for early liver disease in those with 
high-risk obesity or alcohol use and providing appropriate 
interventions and ongoing monitoring.5,9
Tertiary prevention of the consequences of established 
and more severe liver disease includes ongoing 
involvement in the support, monitoring, and management 
of patients with more advanced liver disease, together 
with appropriate referral of patients to secondary care 
services.10 Further developments might include 
appropriately resourced and supported initiatives to move 
areas of care traditionally delivered within secondary care 
to primary care, such as hepatitis C treatment, building 
on innovative models and frameworks already in place.11–13
Substantial work has already been done to raise the 
profiles of these roles for primary care practitioners. The 
Lancet Commission publications have provided several 
recommendations with relevance to primary care.10,14 In 
2016, the Royal College of General Practitioners (RCGP) 
selected liver disease as a one of their clinical priority 
programmes,15 and, in partnership with the British Liver 
Trust, it has recently appointed a primary care Clinical 
Champion for Liver Disease.16 This builds in part on the 
RCGP Nutrition for Health clinical priority programme 
(2011–15), whose RCGP nutrition position statement 
clarified the need for greater primary care action on obesity 
and the role of obesity as a risk factor for liver disease.17 An 
RCGP liver disease position statement will be developed as 
part of this new clinical priority programme, in order to 
benchmark good practice in primary care, and to support 
the translation of new NICE guidance on non-alcoholic 
fatty liver disease (NAFLD) and cirrhosis into service 
delivery, especially where investment in commissioning 
new diagnostic testing facilities is required.
Raising the profile of liver disease within primary care 
requires the development of robust guidance together 
with effective drivers to alter clinical practice.14 These 
include professional training, development of toolkits 
and pathways, and investment in services to facilitate 
increased management of liver conditions within primary 
care.14 Bold investment plus innovative local 
commissioning initiatives will be needed if traditional 
areas of secondary care management, such as hepatitis C 
treatment, are to feature more in primary care as the price 
of new antiviral drugs falls and arrangements through 
the operational delivery networks become less necessary. 
Innovations require a full and realistic awareness of the 
large number of patients at risk of and with early liver 
disease, and the multiple competing workload pressures 
that already exist within primary care.10
As part of moving forwards with the Lancet Commission 
recommendations, a number of metrics have been 
proposed, to assess where we are now, and to guide future 
developments. The metrics agreed to support the Lancet 
Commission’s recommendation 1 are shown in panel 2.
Metric 1: percentage of adult patients in primary care 
who have had body-mass index recorded in the 
preceding year
NAFLD is an increasingly important cause of liver 
disease, including cirrhosis, as obesity rates rise at all 
Panel 2: Metrics for recommendation 1
1·1 Percentage of adult patients in primary care who have had 
body-mass index recorded in the preceding year
1·2 Percentage of adult patients in primary care who have had 
a measure of alcohol consumption or risk in the preceding year
1·.3 Percentage of adult injecting drug users who have had a 
recent hepatitis C virus test 
1·4 Percentage of adult injecting drug users who have had 
hepatitis B virus immunisation 
1·5 Introduction of a suite of Read codes to cover liver disease 
risk factors, diagnoses, and interventions to facilitate 
excellence of clinical care and practice audit and performance 
monitoring
1·6 Referral of all children born at term in the UK with 
conjugated jaundice to a national paediatric liver unit before 
they are 8 weeks old
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ages within the UK, and for this reason assessing the 
percentage of adult patients in primary care who have 
had their body-mass index (BMI) recorded in the 
preceding year is important.18 Primary care is uniquely 
placed to identify obesity, and measuring and recording 
the BMI of a patient in the obese range is the first stage 
to providing in-house interventions or accessing a local 
tiered weight management pathway.
Despite developments in information technology 
within primary care, full data on BMI recording in 
general practice are not easily accessible. The data are 
held neither at the level of the clinical commissioning 
group (CCG) or devolved nation equivalent, nor by the 
relevant national public health body for the four nations 
of the UK. Complete datasets are available at practice 
level, but to access them would require large-scale 
surveys of practices across the UK.
The literature suggests that general practitioners (GPs) 
are not comfortable addressing obesity as a health issue. 
Ogden and Flanagan found that GPs are ambivalent 
about the effectiveness of obesity interventions, finding 
that “obesity does not belong within the medical 
domain”.19,20 In 2004, Hankey and colleagues found that 
less than 10% of GPs had carried out any form of audit to 
determine the prevalence of overweight or obesity in 
their practice population, and that health professionals 
were generally unclear on how to deliver effective weight 
management advice.21 Other published evidence points 
to GPs’ concern about the potential for damaging their 
relationship with their patients by bringing up the issue 
of obesity.22 More recent work has reiterated concerns 
about barriers to case finding and obesity management 
in primary care that centre on uncertainty about the 
evidence base, while signposting useful resources to 
address sensitivities about raising the topic of obesity in 
consultations and other training resources.23
The best data for this metric come from the financial 
incentive quality and outcomes framework (QOF) target 
and payment scheme for GPs. One QOF target has been 
the establishment and maintenance of a register of 
patients aged 16 years and older with a recorded BMI of 
30 or greater in the preceding 12 months. QOF recorded 
prevalence for obesity in England in 2014–15 was 9%, 
representing 4·2 million patients, and obesity had the 
second highest recorded disease prevalence after 
hypertension.24 In Scotland the figure was 8% in 
2014–15,25 and in Wales 9·5% in 2014–15 .26 Data for 
Northern Ireland do not include easily available 
information on obesity as a record of disease prevalence. 
QOF data have limitations, and only relate to those 
people who have had a recent measurement and are 
therefore on each GP practice’s obesity register; they do 
not provide any BMI recordings in those who are 
overweight, or on obese people who are not on the 
practice’s obesity register. The best estimate of the overall 
prevalence of obesity comes from survey evidence. The 
Health Survey for England report27 cited an overall 
prevalence rate for obesity of 25% in England. Similar 
evidence gives an obesity prevalence of 24% in Wales28 
and 28% in Scotland.29
Taken together these figures suggest that around a 
third of those who are obese have had measurement and 
recording of their BMI in primary care in the past 
12 months and two-thirds have not. In the UK the average 
person consults his or her GP six times a year30 and there 
is some evidence to suggest that those who are obese see 
their GPs at a higher rate than average.32
More work is clearly needed to explore the drivers and 
barriers to measuring and managing obesity in primary 
care, and the effectiveness of interventions provided.
Metric 2: percentage of adult patients in primary care 
who have had a measure of alcohol consumption or risk 
in the preceding year
The full range of practice-based data on alcohol use and 
morbidity recording in consultations is not easily 
available, although GPs regularly use standardised and 
coded tools to record alcohol use and related morbidities.
Hazardous and harmful alcohol use is prevalent in the 
UK population. Survey statistics for Scotland show that 
nearly one in four men (23%) and around one in six 
women (17%) women drink at harmful or hazardous 
levels.32 In England, 18% of men and 13% of women 
drink at an increased risk of harm, and 5% of men and 
3% of women drink at higher risk levels.32 Figures for 
Wales9 and Northern Ireland33 are broadly comparable. 
[A: original reference 1 now appears here as 
reference 33]
Alcohol use is related to many areas of social, physical, 
and mental health problems, triggering high rates 
of consultation in primary care. Based on a survey 
conducted by the British Medical Association, the 
Institute for Alcohol Studies estimates that in Scotland 
around 6% of GP consultations are related to ill health 
contributed to by alcohol use.34 An indirect estimate of 
the number of GP consultations contributed to by alcohol 
use in Leeds produced a figure of 10% of all 
consultations.35 Given average consultation rates of five 
per person per year, this totals up to 30 million 
appointments each year across the UK.
However, a consultation for an alcohol-related 
condition does not mean that alcohol use was discussed. 
In their 1998 study, Kaner and colleagues found that GPs 
did not routinely enquire about alcohol use in their 
patients and only one in five GPs felt effective in helping 
a patient to reduce drinking levels.36 Rapley and 
colleagues’ later survey found GPs were in fact routinely 
enquiring about alcohol use, but lack of time and the 
need to manage competing multiple problems within a 
single consultation were the main inhibitors to managing 
a greater number of risky drinkers.37 A policy of brief 
interventions at the time of screening, at presentation 
with hypertension, and when symptomatic could have 
longer lasting effects [A: than GP consultation?].
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Data on direct engagement with alcohol issues in a GP 
consultation can only be sourced indirectly. Until 2015, 
the Practice Team Information (PTI) system collected 
consultation data from general medical practices in 
Scotland. The most recent PTI figures on GP 
consultations give an estimate of 94 630 alcohol 
morbidity-coded primary care consultations by 48 420 
patients in 2012–13, and for the purposes of this metric a 
coded consultation is taken as a proxy measure of a 
primarily alcohol-related consultation.38 Given that 
Scotland has a population of over 4 million adults and a 
harmful and hazardous alcohol use prevalence of around 
20%, it can be estimated that there are 800 000 harmful 
and hazardous drinkers in Scotland. Given that just less 
than 50 000 patients had a primarily alcohol-related 
consultation in one year, this represents just 5% of the 
harmful and hazardous drinking population of Scotland. 
Other evidence points to higher rates of engagement 
with alcohol consumption by GPs, and in a poll of 
English patients in 2004, Aalto found that 11% of those 
visiting their GP had been questioned by their GP about 
their alcohol use, even if briefly.39 Further indirect 
evidence comes from a review of primary health-care 
records for patients who died from alcohol-related 
conditions in Glasgow in 2003. 21% had no record at any 
time of having been advised to abstain from alcohol; 23% 
had received a brief intervention; and 58% had been 
referred to a specialist alcohol service, though a thirdof 
these never attended.40
However, local initiatives have shown that it is possible 
to achieve substantially better performance in primary 
care in this metric area (panel 3, table 1).
Panel 3: The Bolton CCG implementation example (see table 1 for data)
National and local reports surrounding alcohol behaviours 
suggest that Bolton, along with several other parts of North 
West England, is well above the national average for the 
prevalence of problem drinking. Alcohol harm is among the top 
five causes of the life expectancy gap [A: between wealthier 
and poorer people?] for both men and women in the town.41 
A local project was developed to better understand the drinking 
habits and patterns of use and misuse among Bolton’s adult 
population.
The initiative, which has been running now for 5 years, offers an 
AUDIT-C test every 2 years, to all patients aged 16 years and 
older. The primary care development and health improvement 
team, led by Stephen Liversedge, has been working closely with 
GPs and their staff to increase patient awareness of the dangers 
posed to good health and wellbeing from alcohol misuse. 
A pathway for primary care has also been developed.
The latest data show that since April, 2014, 129 867 patients 
have been supported to undertake an AUDIT-C test in primary 
care in Bolton. This accounts for 53·7% of the eligible 
population. Even though all 50 practices in Bolton participate 
in the initiative, some perform better than others [A: do you 
mean some GPs are better than others? If you mean the 
patient population differs between practices, is this 
sentence redundant?]. Table 1 shows local data analysis. [A: as 
tables and figures are required to stand-alone, we have 
moved the group definitions to the table. Please note that 
we are unable to use colours within tables, so the groups are 
shown in table subheadings]
The variability of AUDIT C-data in table 1 shows that practices 
with higher levels of deprivation within their population cohort 
can achieve high activity when appropriate support and modest 
incentives are in place.
As well as meeting the original aim of raising awareness of the 
dangers of alcohol misuse at a population level, this local 
project carries many other benefits:
Provides patient education about the benefits of abstinence 
and information about the risks of excessive drinking Presents 
opportunities for patients who are AUDIT-C positive (score ≥5) 
to have a comprehensive health trainer intervention at the 
surgery to modify unhealthy alcohol-related behaviours
Patients who are high-risk or dependent drinkers are directed to 
local alcohol services
Provides practices with an understanding of an individual’s 
alcohol-related behaviours, which might assist with fvuture 
healthcare
Alerts clinicians to the need to advise individual patients whose 
alcohol consumption might adversely affect their medications
Produces data that can inform commissioning for alcohol 
services
Supplies information to inform future projects
The initial scheme offered practices £2·00 per AUDIT-C 
completed. This was funded from Public Health [A: please 
clarify meaning of ‘from Public Health’], included a training 
day for all clinical staff, and focused on activity. The current 
scheme now sits within the Bolton Quality Contract, which 
commissions for outcomes across 20 standards and 40 key 
performance indicators. All Bolton practices are signed up and 
alcohol screening is one of the key performance indicators. The 
local target for 2016–17 is to have 145 000 current AUDIT-Cs 
completed (60% of the eligible population). Investment has 
been £68 000 over 2 years, which currently equates to 
£0·53 per AUDIT-C completed.
Peer pressure among practices, arising from freely available 
local publication of the data for all Bolton practices, has helped 
to drive engagement, as has the investment in availability of 
in-house health trainers to modify unhealthy alcohol-related 
behaviours.
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Metric 3: percentage of adult injecting drug users who 
have had recent HCV testing
Chronic HCV infection is thought to affect 214 000 people 
in the UK, representing 0·3% of the UK population. 90% 
of these infections have been acquired through injecting 
drug use. An estimated half of those with chronic 
hepatitis C infection are undiagnosed.42
A high proportion of current psychoactive drug users 
attend services for treatment, and data on testing are 
routinely submitted to local commissioners by all drug 
services and collated by public health bodies in a number 
of [A: please clarify] reports. Further information is 
available via the Unlinked Anonymous Monitoring 
(UAM) survey of people who inject drugs in contact with 
drug services.
Drug misuse treatment is characterised by multiple 
treatment episodes and drug service patients have a 
comprehensive assessment at the start of each treatment 
episode which routinely covers HCV risk. In the UK in 
2013–14, 87% of patients had been offered a hepatitis C 
test at the beginning of their most recent treatment 
episode, and of those more than two-thirds (67%) 
accepted the offer.42 Around half of those who inject 
psychoactive drugs are typically found to be hepatitis C 
antibody positive.8
Number of 
registered 
patients aged 
≥16 years
Number of 
AUDIT-Cs 
done
Proportion 
of patients 
aged 
≥16 years 
receiving 
AUDIT-C
Peer 
average for 
proportion 
of patients 
aged 
≥16 years 
receiving 
AUDIT-C
High deprivation, BME, young (IMD 50·75–41·23)
1 1523 1180 77·5% 72·5%
2 2297 2071 90·2%
3 2274 2144 94·3%
4 1021 891 87·3%
5 2965 2403 81·0%
6 2626 1340 51·0%
7 4557 2487 54·6%
High to mid deprivation, BME/mixed ethnicity, young/normal 
(IMD 51·88–38·15)
8 3545 3043 85·8% 64·5%
9 3056 1374 45··0%
10 2717 1631 60·0%
11 3228 1115 34·5%
12 3161 1733 54·8%
13 1487 1109 74·6%
14 1610 1272 79·0%
15 1984 1623 81·8%
16 1634 1082 66·2%
17 3236 2048 63·3%
18 6009 4393 73·1%
Mid deprivation, mixed ethnicity, normal (IMD 40·40–26·84)
19 6476 4171 64·4% 55·0%
20 1710 766 44·8%
21 2752 1469 53·4%
22 2374 1196 50·4%
23 3152 2025 64·2%
24 3941 2106 53·4%
25 9378 5229 55·8%
26 4089 1659 40·6%
Mid deprivation, white, normal (IMD 44·95–34·71)
27 10 750 6251 58·1% 56·9%
28 5440 2591 47·6%
29 5176 1718 33·2%
30 4043 2352 58·2%
31 2647 1474 55·7%
32 5050 3805 75·3%
33 8325 5510 66·2%
34 5090 2760 54·2%
(Continues in next column)
Number of 
registered 
patients aged 
≥16 years
Number of 
AUDIT-Cs 
done
Proportion 
of patients 
aged 
≥16 years 
receiving 
AUDIT-C
Peer 
average for 
proportion 
of patients 
aged 
≥16 years 
receiving 
AUDIT-C
(Table continued from previous column)
Mid to low deprivation, white, normal/old (IMD 32·77–23·37)
35 4905 2465 50·3% 42·0%
36 4024 2412 59·9%
37 3281 2203 67·1%
38 10 558 3764 35·7%
39 4877 2255 46·2%
40 2479 1242 50·1%
41 6149 2402 39·1%
42 10971 3114 28·4%
Low deprivation, white, normal/old (IMD 21·18–9·76)
43 8424 4826 57·3% 49·2%
44 6254 3555 56·8%
45 12 201 4861 39·8%
46 6212 3834 61·7%
47 16 653 7676 46·1%
48 8075 3004 37·2%
49 2311 1131 48·9%
50 4953 3102 62·6%
All practices
Total 241 650 129 867 53·7% ..
[A: column headings have been edited for clarity, please check that they are 
correct] Data are for April, 2014, to June, 2016 [A: correct?]. BME=black and 
minority ethnicity. IMD=index of multiple deprivation. [A: please add brief 
definitions for young, normal, and old]
Table 1: Patients undertaking AUDIT-C test in NHS primary care 
practices within Bolton CCG, clustered by deprivation, age [A: mean/
median age? If not, please specify how age is defined], and ethnicity 
[A: ie, majority ethnic group? If not, please clarify how ethnicity is 
defined]
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In England and Wales, among those who inject only 
performance and image enhancing drugs, 3·6% have 
antibodies to hepatitis C. Only 32% report ever having 
been tested for hepatitis C. In Scotland, among those 
who had only injected image-enhancing [A: addition of 
‘enhancing’ correct?] and performance drugs during the 
last 6 months, 5·1% had antibodies to hepatitis C in 
2013–14 and just under a third (29%) reported ever being 
tested for hepatitis C. This had increased from 18% in 
2010.42 As this group does not use traditional drug 
services, opportunities for HCV testing are needed 
outside drug treatment facilities.
Testing also takes place in general practice, and testing 
rates have increased year-on-year between 2010 and 2014, 
rising by 5% between 2013 and 2014, representing 
60 000 tests across 23 sentinel laboratories each year.42 
This suggests that awareness of HCV infection in the 
primary care setting is increasing, and this is particularly 
important for people who acquired the infection from 
historical injecting drug use and who might not have 
attended drug treatment services for many years, and for 
those who acquired the infection via an alternative route 
such as historical blood product transfusion, tattooing, or 
body piercing. It has been estimated that around 50% of 
individuals with chronic hepatitis C infection are not in 
contact with drug treatment services, and accessing more 
comprehensive data on testing in primary care will be of 
increasing importance.
Testing for HCV infection in the prison setting is 
particularly important as this population represents a 
particularly high-risk group. Data from several different 
sources suggest significant and continuing under-testing 
of this population group,8 but rates of testing for HCV 
rose from 5·3% of new admissions to prison in 2010–11 
to 8·6% in 2013–14.
Metric 4: percentage of adult injecting drug users who 
have had HBV immunisation
Hepatitis B virus (HBV) is transmitted by parenteral 
exposure to infected blood or body fluids, and 
transmission in the UK is predominantly through sexual 
contact, blood-to-blood contact (eg, sharing of needles 
and other equipment by injecting drug users or 
needlestick injuries), or through perinatal transmission 
from mother to child. Data on HBV immunisation in 
sexual health clinics and primary care practices are not 
available, and the following metrics are focused on those 
who are at risk from injecting drug use and who are in 
contact with drug services. The data are taken from 
collated information provided routinely by drug services 
and from the Unlinked Anonymous Monitoring survey
In England, Wales, and Northern Ireland, reported 
uptake of the vaccine (ie, receiving at least one dose of 
vaccine) for those who inject psychoactive drugs 
increased from around half in 2004 to almost three-
quarters in 2014. However, the level of uptake declined 
from 76% in 2011 to 72% in 2014. Among injecting drug 
users surveyed in 2014 who had never been infected with 
hepatitis B and who had taken up vaccination, 61% had 
received three or more doses of the vaccine and had 
completed the course of immunisation. Of those who 
had not taken up vaccination 55% (219 of 396) were 
currently receiving a prescribed substitute drug as part 
of drug service provision. The non-immunised group 
used other health services where vaccination could have 
been offered; 62% (247 of 397) had seen a general 
practitioner; 26% (103 of 397) had attended an emergency 
department; 14% (56 of 397) had used a walk-in or minor 
injury clinic; and 7·8% (31 of 397) had attended a 
genitourinary medicine clinic.42 These contacts represent 
lost opportunities for vaccination as part of primary 
prevention. Among people injecting image-enhancing 
and performance-enhancing drugs in England and 
Wales only 40% reported uptake of the vaccine against 
hepatitis B.42
Metric 5: draft and adopt a suite of Read codes to cover 
liver disease risk factors, diagnoses, and interventions to 
facilitate excellence of clinical care and practice audit and 
performance monitoring
Review by the commission team has identified an 
opportunity to develop a comprehensive set of Read 
codes (the standard clinical terminology system used in 
general practice in the UK) [A: definition of Read codes 
added for the benefit of readers who may not be aware of 
the term–ok?] relevant to both prevention and 
management of liver disease and associated risk factors. 
This project will be taken forwards by the Commission 
team over the next year.
Metric 6: to ensure that all children born at term in the 
UK with conjugated jaundice are referred to a national 
paediatric liver unit before they are 8 weeks old
Currently all children with significant neonatal liver 
disease [A: please clarify this. What types of neonatal liver 
disease are deemed significant/non-significant?] are 
referred to one of the three national liver units. National 
data is collected on the age at which Kasai portoenterostomy 
Panel 4: Metrics for recommendation 2
2·1 Number of DGHs with liver units (>2 consultant 
hepatologists)
2·2 Number of regional specialist units
2·3 Number of consultant hepatologists in post
2·4 Number of DGHs with 24-hour emergency endoscopy 
cover
2·5 Number of DGHs enrolled into QuEST programme
2·6 Number of DGHs with multidisciplinary alcohol care 
teams
DGH=district general hospital·
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is done [A: correct as edited?] for biliary atresia and the 
outcome. Between January, 2009, and December, 2013, 
230 children were diagnosed with biliary atresia in 
England and Wales; 75 (32·6%) were older than the 
recommended age for operation (ie, >56 days old) at time 
of Kasai portoenterostomy or laparotomy, and seven of 
75 had a primary transplant.33 Further education and 
awareness of the importance of early diagnosis of neonatal 
liver disease will be addressed through initiatives from 
PHE and the Children’s Liver Disease Foundation (CLDF).
Recommendation 2: establishment of acute 
liver services in district general hospitals linked 
with 30 regional specialist centres for more 
complex investigations and treatment, and 
increased provision of medical and nursing 
training in hepatology
[A: please add a subheading for this section (the 
template requires use of an introductory subheading if 
subheadings are to be used later in the section)]
In presenting the metrics for this recommendation 
(panel 4), Mark Hudson and Jessica Dyson have obtained 
up to date figures on hospital staffing levels and facilities 
for liver disease in the UK through a new survey of 
hospital trusts. Of the 207 hospitals approached, 100% 
provided information. Overall, a total of 221 whole 
time equivalent (WTE) consultant hepatologists and 
305.7 [A: 305·7 WTEs?] gastroenterologists with an 
interest in hepatology were identified. The data for the 
devolved countries are provided in table 2 and expressed 
as WTE per 100 000 population. The provision of liver 
services as defined by WTE staffing levels in the UK is 
summarised in figure 2. Outside of transplant centres, 
only 21 (10%) centres have three or more hepatologists, 
meeting the criteria for large units coming within the 
category of specialist regional centres. Only 16 of the 
remaining hospitals in the UK would meet the criteria 
Consultant hepatologists (WTE) Number of acute 
DGH (≥2 WTE 
hepatologists and 
≥2 gastroenterologists 
with interest in 
hepatology)
Number of level 2 
regional specialist 
liver units (services)
Number of large 
regional specialist 
liver units (≥3 WTE 
hepatologists)
Units (excluding 
large centres) 
with 24 h OOH; n 
(%) able to 
manage varices
TIPSS 
provision
UK 221; 0·34 per 105 population 
(64·9 million)
16 23 (excluding 
7 transplant centres)
21 (excluding 
7 transplant centres)
143/183 (78%); 
[120/143 (84%)
44/207 (21%)
England 193·8; 0·35 per 105 population 
(54·7 million)
16 18 (excluding 
6 transplant centres)
18 (excluding 
6 transplant centres)
117/135 (87%); 
[104/117 (89%)]
34/159 (21%)
Scotland 20·6; 0·39 per 105 population 
(5·3 million)
0 3 (excluding 
1 transplant centre)
2 (excluding 
1 transplant centre)
13/22 (59%); 
[8/13 (62%)]
8/22 (36%)
Wales 2·6; 0·08 per 105 population 
(3·1 million)
0 1 0 5/16 (31%) 
[5/5 (100%)]
1/16 (6%)
Northern 
Ireland
4; 0·22 per 105 population 
(1·8 million)
0 1 1 8/10 (80%) 
[3/8 (38%)]
1/10 (10%)
WTE=whole time equivalent. DGH=district general hospital. OOH=out-of-hours service. [A: definition correct?] TIPSS=transjugular intrahepatic porto-systemic shunt.
Table 2: Summary for UK and devolved nations of hepatologists per 100 000 population, hepatology provision in terms of staffing levels, level 2 services, 
endoscopy and TIPSS service, and enrolment in LIVER QuEST
Lowest
Highest
Regions
Liver disease hospital admission rates
Lower-tier local authorities
Transplant unit
Large liver unit
DGH—meets liver unit criteria
DGH—does not meet liver unit criteria
Liver services
Figure 2: Distribution of liver services in England in relation to hospital admissions for liver disease in people 
of all ages, directly standardised rates per 100 000 population, 2014–15
Map prepared under licence by Public Health England. © Crown copyright and database right 2016. 
[A: please confirm that you have obtained formal permission to use]
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for an adequately staffed acute service (two hepatologists 
and two or more gastroenterologists with an interest in 
hepatology).
Considering England alone, 193·8 WTE consultant 
hepatologists were identified, compared to 122 in 2010;43 
a 59% increase. However, 54·7 (28%) of these were in the 
six English transplant centres and 69·6 (36%) were in the 
18 large units within the category of specialist regional 
centres. Of the remaining 135 hospitals, only 16 (12%) 
meet the criteria for an adequately staffed district general 
hospital acute service (two hepatologists and at least two 
gastroenterologists with an interest in hepatology).
As well as stratifying centres in terms of the numbers 
of WTE consultant hepatologists, the survey also looked 
at the services provided. A level 2 specialist centre 
is defined as one that provides: out-of-hours 
endoscopy including the management of varices; 
transjugular intrahepatic porto-systemic shunts (TIPSS); 
a regular hepatocellular cancer or hepato-pancreato-
biliary multidisciplinary team meeting; medical 
locoregional treatment for hepatocellular cancer; antiviral 
treatment for hepatitis C (in England as part of an HCV 
operational delivery network); liver histopathology; 
dedicated liver clinics; and has a specialist nurse team.
Using this definition, only 18 centres in England, 
three in Scotland (outside of the liver transplant 
centres), one in Wales, and one in Northern Ireland 
meet the level 2 criteria for a specialist liver unit. It is 
also noteworthy that five of the 21 large centres (with ≥3 
hepatologists) in the UK do not meet these criteria, 
although seven of the 179 centres that have more than 
three WTE hepatologists can provide these services. 
Mapping of the district general hospitals and regional 
specialist centres against liver disease hospital 
admissions and standard mortality rates for liver disease 
in England are shown in figures 2 and 3. The maps 
suggest that there is now reasonable availability of 
specialist liver services in the majority of regions in 
England, particularly if the hepatitis C operational 
delivery networks are included. However, there remain 
many district general hospitals that have inadequate 
hepatology support. In England, 55% (88) of all hospitals 
do not have a specialist hepatologist and 47 (30%) do not 
have a dedicated liver clinic (excluding viral hepatitis). 
Figure 4 summarises the provision of liver services as 
defined by staffing levels in the UK. [A: ok to cite figure 
4 here?]
The NCEPOD report in July, 2015,43,44 highlighted 
major deficiencies in the care received by patients 
suffering severe gastrointestinal haemorrhage as a 
consequence of cirrhosis and variceal bleeding. The 
mortality rate was high at 32%, with 37% not receiving 
prophylactic antibiotics despite recommendations in all 
guidelines and strong evidence that this reduces 
mortality.45,46 Despite the failure to control bleeding in 
almost a third of patients, only 13 hospitals reported 
having a 24-h TIPSS service. The findings in the liver 
survey with respect to out-of-hours provision for 
endoscopy are summarised in table 2. The data for 
England excludes the transplant and large units. The 
provision of out-of-hours endoscopy services varied 
widely between the devolved nations. In England, 
117 (87%) of hospitals provide emergency 24-h endoscopy 
cover although only 104 of these can manage varices. In 
Scotland, Wales, and Northern Ireland, 59% (62%), 
31% (100%), and 80% (38%) of centres provide 24-h 
endoscopy cover, respectively (with the figures in 
brackets representing the proportion of endoscopists 
who are able to manage varices). Of the 34 centres in 
England recording a TIPSS service, 14 perform fewer 
than ten procedures per year, and in Scotland, three of 
the eight centres providing TIPSS performed fewer than 
five in the past year (table 2) which must raise concerns 
as to the safety and sustainability of such services. In 
Wales and Northern Ireland, there are single centres for 
the whole country, making access for emergency 
procedures difficult.
Lowest
Highest
Regions
Liver disease mortality rates
Lower-tier local authorities
Transplant unit
Large liver unit
DGH—meets liver unit criteria
DGH—does not meet liver unit criteria
Liver services
Figure 3: Distribution of liver services in England in relation to liver disease mortality in people of all ages, 
directly standardised rates per 100 000 population, 2013–15
Map prepared under licence by Public Health England. © Crown copyright and database right 2016. 
[A: please confirm that you have obtained formal permission to reproduce] [A: Figure legend same as as Figure 2?
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The survey also collated information regarding 
numbers of liver nurse specialists and viral hepatitis 
nurse specialists. These are presented in table 3, which 
again highlights the wide variation between the devolved 
nations per 100 000 of the population.
Number of district general hospitals with 
multidisciplinary alcohol care teams
The proportion of hospitals providing some level of 
alcohol liaison service is similar across each of the nations 
in the UK. However, the number of hospitals with formal, 
multidisciplinary alcohol care teams is uncertain. The 
evidence base for the role of alcohol care teams, together 
with the six key elements of a model team, are well 
described.47 The establishment of a consultant-led, 
multidisciplinary alcohol care team and a 7-day alcohol 
specialist nurse service were also two of the principal 
recommendations of the NCEPOD report,48 which 
highlighted the delays in referral of patients for specialist 
care and missed opportunities for brief interventions 
during previous admissions. The present survey shows 
uncertainty in the number with formal multidisciplinary 
alcohol care teams, although some level of alcohol team 
was present in the majority of hospitals in England and 
the devolved nations. In a small, local, London-based 
survey in 2009, only 10% of hospitals surveyed had a 
multidisciplinary alcohol care team consultant lead and 
42% had an alcohol specialist nurse service.49
In 2014, PHE published data on hospital alcohol care 
teams and alcohol specialist nurses.50 Encouragingly, in a 
2015—16 follow-up survey, at least 76 out of a total of 116 
hospitals surveyed (66%) had a consultant lead. Around 
45% were led by gastroenterology or hepatology, 18% by 
psychiatry, and 11% by emergency medicine. Almost a 
quarter of services were clinically led by nurses. However, 
only 68% of hospital that responded to PHE’s 2015 survey 
have teams staffed adequately to provide seven day cover 
and deliver the potential impact demonstrated by Royal 
Bolton or Salford.47
PHE analysis of secondary care alcohol specialist services 
has identified that, regardless of geographical location or 
size of hospital, the most effective alcohol care teams are 
those providing a seven day service, led by a senior clinician 
with dedicated time for the team and evidence-based 
interventions. Alcohol care teams facilitate identification 
of alcohol misusers in hospitals and deliver appropriate 
packages of care provided by multidisciplinary teams. This 
requires dedicated sessional input from senior clinicians 
and at least three other clinical staff in order to facilitate 
seven day working throughout the year.
Care bundles and Liver QuEST accreditation
Some progress has been made during this year with 
development of the cirrhosis care bundle to standardise 
early treatment (within 24 hours of admission to hospital) 
for patients with decompensated cirrhosis. Results of 
implementation of the bundle, which has been piloted in 
the Newcastle upon Tyne NHS Hospitals Foundation 
Trust as a successful Commissioning for Quality and 
Innovation (CQUIN) target, show that patients with a 
completed care bundle are more likely to have appropriate 
management. A comparison of pre-bundle and post-
bundle audit data from three English hospitals showed 
that patients with a completed care bundle are significantly 
more likely to undergo a diagnostic ascitic tap to exclude 
spontaneous bacterial peritonitis (p=0·020), have an 
accurate alcohol history documented (p<0·0001), and be 
given prophylactic antibiotics following variceal 
haemorrhage (p=0·0096).51
Transplant unit
(3%)None
(11%) Large centre
(10%)
In between
(68%)
DGH
(8%)
Figure 4: Provision of liver services as defined by WTE staffing levels in the UK 
[A: are these figures for 2016?]
Large centre=three or more WTE hepatologists, DGH=two hepatologists and 
two or more gastroenterologists with an interest in hepatology, none=no WTE 
hepatologists or gastroenterologists with an interest in hepatology, 
in-between=anything between DGH criteria and none.
Liver nurse specialists Viral hepatitis nurse 
specialists
Alcohol 
liaison service
UK 163·5; 0·25 per 100 000 population 
(64·9 million)
223·5; 
0·34 per 100 000 population
171/207 
(83%)
England 134; 0·24 per 100 000 population 
(54·7 million)
175; 
0·32 per 100 000 population
133/159 
(84%)
Scotland 18; 0·34 per 100 000 population 
(5·3 million)
31; 
0·58 per 100 000 population
18/22 
(82%)
Wales 9·5; 0·31 per 100 000 population 
(3·1 million)
15·5; 
0·5 per 100 000 population
12/16 
(75%)
Northern 
Ireland
2; 0·11 per 100 000 population 
(1·8 million)
2; 
0·11 per 100 000 population
8/10 
(80%)
Table 3: Summary for UK and individual nations of specialist nurse provision, alcohol liaison services, and 
liver fellows
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Some progress has also been made in implementation of 
the Liver Quality Enhancement Service Tool (Liver QuEST) 
project for accreditation of hospital services. Liver QuEST 
is an evolving quality assurance framework that aims to 
improve the care of patients with liver disease across 
England.52 The project is sponsored by the Royal College of 
Physicians and has the backing of the patient groups, the 
British Society of Gastroenterology, the British Association 
for the Study of the Liver, and the Lancet Commission. This 
process has been piloted in six units across England and 
the learning from these visits was recently reviewed. Early 
themes arising from the review process include an 
underutilisation of information technology and a failure in 
simple key performance indicators in emergency care 
(such as antibiotic prescription in variceal bleeding). To 
date 24 hospitals have engaged with Liver QuEST, including 
eight DGHs. The project currently uses the operational 
delivery networks associated with hepatitis C. It is also 
working with NHS Wales to involve their liver services 
within the scheme, with a plan to involve the other devolved 
nations over the coming year.
Recommendation 3: a national review of liver 
transplantation to ensure better access for 
patients and to increase capacity
Panel 5 shows metrics for recommendation 3. The rate 
of liver transplant activity is the primary metric of 
performance. The number of transplantations done in 
2015—16 was 917 and in line with activity over the last 
three years. There was a 4% decrease in the number of 
patients on the waiting list on March 31, 2016. The 
transplantation rates fall short of the targets set by the 
NHS Blood and Transplant T2020 strategic review.
The Lancet Commission continues to hold the view 
that liver transplant services should be subjected to a 
fundamental review, but there is no evidence to date that 
this will be forthcoming. However, the first formal peer 
review process of individual programmes is scheduled 
for late 2016. An extensive range of quantitative measures 
will be evaluated that measure performance against 
agreed national service specifications as well as outcomes, 
and there might be an opportunity to scope capacity for 
expansion if the increase in donor organs materialises.
Equity of access to liver transplant services and the rate 
of organ utilisation across all the programmes are cardinal 
metrics of performance. The most recent report on liver 
transplantation published by NHS Blood and Transplant 
confirms the continuing crude differences by geographical 
region and access to liver transplantation. The highest 
transplant rates per million population were in Scotland 
(19·1) and Northern Ireland (17·9) and the lowest in the 
south of England (9·3). The remaining Strategic Health 
Authority areas had rates in the 13·0–14·4 range.
Waiting times and the risk of death on the waiting list are 
also dimensions of equity of access and historically there 
have been substantial differences between centres in these 
parameters. The metrics designed to monitor this aspect 
are transplant activity rates normalised to the size of the 
waiting list, and the waiting times to transplantation for 
each of the blood groups. However, substantial progress 
has been made to direct organs preferentially to the 
patients most likely to benefit from the transplant, aiming 
to maximise use of donated organs. A new national 
offering sequence is scheduled to operate from summer 
2017. The first offer of an organ will no longer be directed 
to centres but to the highest ranked patient in the country. 
The new system should improve equity of access and is 
expected to reduce mortality on the waiting list by 50%. 
Another dimension of equity of access is consistency in 
the comorbidity profiles considered acceptable in patients 
being listed for liver transplantation.
The percentage of livers retrieved but not transplanted 
has increased from 8·2% to 16·6% over the past decade, 
with a 4% point increase in the last two years. While the 
cause of this trend is likely to be multifactorial, the 
possibility that it includes an element of impaired ability to 
cope within the service needs [A: who is failing to cope? 
Please clarify] to be given due consideration. However, 
organ utilisation should be consistent across the service, 
and two metrics to track this have been designed: the 
acceptance rate on first offer of a whole organ; and the use 
of organs falling within an agreed definition of marginal 
organs. At present, practice varies considerably between 
centres, with higher decline rates in those centres with 
shorter waiting lists. The extent to which these differences 
are logistical or cultural needs to be clarified.
Recommendation 4: specialist paediatric services 
and continuity of care in transition arrangements 
for children with liver disease reaching adult life
Panel 6 shows the metrics for recommendation 4. 
Between 2008 and 2015, 667 young people transitioned 
into adult services from national paediatric liver units at 
Panel 5: Metrics for recommendation 3
3·1 Number of patients treated
3·2 Transplant activity normalised to waiting list
3·3 Waiting time to transplant normalised by blood group
3·4 Primary offer acceptance rate of used whole organs
3·5 Use of marginal donors
Panel 6: Metrics for recommendation 4 
4·1 Reduction in outpatient did not attend (DNA) rates in 
patients transitioned to adult services in the three main liver 
centres to less than 15%
4·2 Reduction in graft loss or death in 16–24 year olds post-
transition 
4·3 Educate adult physicians in paediatric liver disease and 
transition to adult services by supplementing adult curriculum
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Birmingham Children’s Hospital and King’s College 
Hospital, of whom 17 died (2·5%) [A: please add numbers 
for death after transplant and from liver disease (as in 
originally supplied table 4), if you wish. In the submitted 
manuscript, the table showed only 10 deaths, for 2008-
2013. The table has been deleted because it is easy to give 
the data in the text and this requires less space. I have 
assumed that you only want to present the data for 2008-
2015, but if you also want to include the numbers for 
2008-13 to show the difference over time, please add a 
sentence to the text.] . Historic data from all three national 
centres (Birmingham Children’s Hospital, King’s College 
Hospital, and Leeds) showed that approximately 22% did 
not attend outpatient clinics in adult services despite a 
specialist transition service53 (M Samyn, unpublished) 
highlighting the need for more focused management and 
support. [A: ref 54 changed to an in-text citation, as 
unpublished work cannot be not included in the reference 
list. Subsequent references have been renumbered. 
Please check that references are correctly cited.]
The three national paediatric liver centres are now 
using a validated self-management tool to empower 
young people to manage their condition and identify 
specific areas where more multidisciplinary support is 
required to facilitate the transition process.
Recognition that additional education and training for 
adult hepatologists on childhood liver disease is needed 
has led to the development of a draft curriculum, which 
has been submitted to the relevant specialist committees 
for inclusion in core training for gastroenterology and 
hepatology.
Recommendation 5: measures to reduce overall 
alcohol consumption in the country
Metric 5·1: policy metrics
Panel 7 shows the metrics for recommendation 5, and 
table 4 summarises policies across the UK. [A: Sentence 
inserted to provide citations for panel and tables in the 
main text; please confirm that wording is ok. The two 
reports cited in the table have been added to the reference 
list and subsequent references renumbered.] In 
March, 2012, David Cameron, then Prime Minister, 
stated: “When beer is cheaper than water, it’s just too easy 
for people to get drunk on cheap alcohol at home before 
they even set foot in the pub. So we are going to introduce 
a new minimum unit price (MUP). For the first time it 
will be illegal for shops to sell alcohol for less than this set 
price per unit. We are consulting on the actual price, but 
if it is 40p that could mean 50 000 fewer crimes each year 
and 900 fewer alcohol-related deaths a year by the end of 
the decade.” He went on to say: “Of course, I know the 
proposals in this strategy won’t be universally popular. 
But the responsibility of being in government isn’t always 
about doing the popular thing. It’s about doing the right 
thing.” However, minimum unit pricing was postponed 
indefinitely following lobbying from the drinks 
industry56,57 and the government has made no moves to 
Panel 7: Metrics for recommendation 5
5·1 Policy metrics
5·2 Overall alcohol consumption in country 
5·3 Number of hospital admissions from alcoholic liver disease 
5·4 Number of deaths directly due to alcohol consumption 
5·5 In-hospital mortality from alcoholic liver disease 
5·6 Hospital and community alcohol services
5·7 Survivals for liver admissions
England Wales Scotland Northern Ireland
Minimum unit pricing Opposed to minimum unit 
pricing
Legislation in progress Minimum unit pricing bill 
passed, legal verdict 
awaited
Legislation in progress
Taxation Not devolved; tax cuts to drinks 
industry worth £3·55 billion 
according to 5-year Treasury 
projections since 2013
Not devolved; tax cuts to 
drinks industry worth £3·55 
billion according to 5-year 
Treasury projections since 
2013
Not devolved; tax cuts to 
drinks industry worth 
£3·55 billion according to 
5-year Treasury 
projections since 2013
Not devolved; tax cuts to 
drinks industry worth £3·55 
billion according to 5-year 
Treasury projections since 
2013
Health information PHE report awaited Outlined in Working Together 
to Reduce Harm54
Information by disease 
aetiology, good quality 
data on HCV and 
advanced alcohol-related 
liver disease, using routine 
data sources
Improved health information 
outlined in New Strategic 
Direction for Alcohol and Drugs55
Protection of children from 
alcohol marketing
PHE report awaited Welsh Assembly pressing UK 
government for change
Remains aspirational Not devolved
Countering drink industry Industry influence has probably 
never been higher
No clear policy Trying to develop a 
consensual approach
No clear policy
[A: the Powerpoint files supplied included some rows that were not present in the Word version of the manuscript. I have added these rows to the table, but please 
let me know if they should not be included]
Table 4: Policy metrics
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bring forward any effective measures since, such as 
protection of children from alcohol marketing.
There have been two subsequent developments. PHE 
was commissioned by the UK and devolved governments 
to produce two reports, one of UK alcohol policy and a 
further report of alcohol related harm to third parties—
ie, people harmed as a result of drinking by other people. 
PHE has formally reviewed the evidence for alcohol 
policy, and is due to publish this report in late 2016.
The UK Chief Medical Officers published reviewed 
drinking guidelines in January, 2016, stating that any 
amount of alcohol intake can increase the risk of 
developing a range of illnesses, recommending a weekly 
intake of no more than 14 units with several drink-free 
days each week.58 [A: the reference originally cited 
here was the 1995 guideline, please add the correct 
reference to the list]The report did not address higher 
risk and harmful drinking, but did conclude that since 
the previous guideline in 1995,59 new evidence has 
outlined that the risk of cancer starts from zero alcohol 
intake and rises in a linear fashion. The report also 
addresses the putative health benefits of alcohol, 
concluding that this evidence was considered less strong 
than had been considered previously [A: correct?], and 
that a reduced risk in the UK is significant only for 
women aged 55 years or older. The 14-unit guideline on 
regular drinking would be consistent with a little under a 
1% lifetime risk of death from alcohol for people who 
follow this consistently.58
Metric 5·2: alcohol consumption 
Sources of data for alcohol consumption include HM 
Revenue and Customs (HMRC) receipts and population 
surveys, with surveys recording 55–60% of the 
consumption recorded by HMRC. Data from HMRC 
clearance [A: please briefly define ‘clearance’] show 
increasing gradually consumption of alcohol in the UK 
until 2008, when the 2% above inflation duty escalator 
was introduced (figure 5). Consumption then transiently 
decreased, but it is now rising strongly once more. There 
has also been marked shift towards the consumption of 
stronger alcohol, with a decrease in consumption of beer, 
and increased consumption of wine, spirits, and cider.60
The UK Opinions and Lifestyle Survey found that 58% 
of the UK population had drunk alcohol in the previous 
week, with around 18% of the highest earners drinking 
on five or more days, compared with 8% of lowest 
earners. Wales (13%) had the highest proportion of 
people drinking more than 14 units a week, compared 
with Scotland (12%) and England (8%).
Analysis of Health Survey England (HSE) data from 
2014 for the total amount of alcohol consumed by 
drinkers categorised by level of weekly consumption 
(table 5) shows that 24% of alcohol was consumed by 
low-risk drinkers and 76% by higher-risk drinkers, of 
which 52% was consumed by people drinking more than 
twice the amount recommended in guidelines.61 
Comparing the distribution with HSE data from 1991–92, 
the proportion of alcohol consumed by extreme drinkers 
drinking more than 75 units a week has increased from 
13% to 17%.
Metrics 5·3 and 5·4: alcohol-related hospital episodes 
and deaths
Trends in alcohol-related hospital episodes for England 
show a steady increase peaking in 2012, and relative 
stability in the 2 years since (figure 6). [A: citation of 
figure 6 here ok?] Directly attributable alcohol-related 
deaths increased steadily in England and Wales 
throughout the 1980s, 1990s, and 2000s. The majority of 
these deaths were a result of alcohol-related liver disease, 
and there is a relationship between alcohol-related deaths 
and increasing affordability of alcohol, as alcohol duties 
were not increased in line with incomes (figure 7). 
[A: correct to cite figure 7 here (not figure 3, as originally 
stated)? Reference cited in figure legend renumbered in 
1991–92 cohort 2014 cohort
Count Column 
N %
Sum Column 
sum %
Count Column 
N %
Sum Column 
sum %
None 678 9·6% 0 0% 1434 18·6% 0 0%
>0–14 4686 66·4% 19 040 25·2% 4633 60·0% 19 176 24·6%
15–28 960 13·6% 19 363 25·6% 922 11·9% 18 841 24·2%
29–75 641 9·1% 27 463 36·3% 629 8·2% 27 051 34·7%
≥75 88 1·2% 9751 12·9% 98 1·3% 12 830 16·5%
The proportion of teetotallers doubled; that of extreme drinkers increased slightly from 1·2% to 1·3%, whereas the 
proportion of total alcohol consumed by extreme drinkers increased from 13% to 17% (Yates χ2 p<0·0001). [A: please 
clarify meaning of ‘count’ and ‘sum’ in the column headings]
Table 5: Analysis of HSE data from 1991–92 and 2014 with total amount of weekly units consumed, 
categorised by weekly alcohol rating
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Figure 5: HMRC alcohol clearance in the UK, 1990–91 to 2015–16
[A: please define ‘HL’ (used in y axis label]
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line with this placement in the text.] The patients dying 
of directly alcohol-related causes are extreme drinkers; 
the average weekly consumption of patients with alcohol-
related cirrhosis is around 150 units, and that of patients 
with alcohol dependency is even higher, at around 
180 units, so on the whole these patients are drinking the 
cheapest alcohol they can find.63,64 Alcohol-related deaths 
are strongly linked to health inequalities; many of these 
patients are already spending much of their disposable 
income on alcohol and are sensitive to price changes.65,66
In the 2008 government budget, alcohol duty was 
increased and a 2% above inflation escalator introduced. 
The subsequent decrease in affordability coincided with 
a change in the trend in alcohol related mortality. We 
hypothesised that this change was a direct result of 
changes in the price of alcohol combined with the impact 
of an economic downturn on incomes67 and predicted 
that alcohol mortality would rise following the 2013 
repeal of the 2% duty escalator and the subsequent tax 
cuts. [A: should ref 68 be cited here instead of in the 
following sentence?] Alcohol-related deaths increased in 
2014 (reported November, 2015) and the figures for 2015 
will be reported in November, 2016.68, 69[A: ref 69 was a 
duplicate of ref 68, please add the citation for the 2015 
report to the reference list instead]
Data for Scotland for this metric, compiled from data 
collected by the Office for National Statistics,70 are 
presented in graphic form within the report from 
Scotland later in this paper. The graph shows the number 
of deaths registered each year against the 5-year moving 
average and demonstrates a year-on-year increase from 
1992, peaking in 2002. Since that date there has been a 
series of staggered decreases to the 2015 level of around 
1100 deaths per annum.
Metric 5·5: alcohol-related deaths [A: should this be “In-
hospital mortality from alcoholic liver disease”, as in the 
panel? If not, should the paragraphs below be part of 
the previous section, and should there be an additional 
section on in-hospital deaths?]
Figure 8 shows in-hospital mortality of liver disease for 
acute trusts in England. [A: correct to add citation of 
figure 8 here? If not, please advise as to where it should 
be cited] In 2015, there were 1150 alcohol-related deaths, 
a decrease of 2 [A: ie, two deaths?] (0·2%) compared with 
2014 on the basis of the current definition, and the third 
lowest annual total since 1997. The number of 
alcohol-related deaths was relatively stable, at roughly 
600 per year, during the 1980s. It then increased rapidly 
during the 1990s and early 2000s, to around 1500 per year 
in the mid-2000s. The figure of 1546 in 2006 was the 
largest so far recorded; since then, the trend has been 
generally downward, as the rises in some years have 
been small (compared to the falls in the other years) and 
could well be due to year-to-year variability. Deaths in 
2015 consisted of 764 male deaths and 386 female deaths, 
continuing a long-term pattern.71
There were approximately 16 chronic liver disease 
deaths per 100 000 population in Scotland in 2014, similar 
to the rate in 2013. In 2014, male mortality rates for 
chronic liver disease were twice as high as those reported 
for women (21 per 100 000 compared with 10 per 100 000 
population). Between 1993 and 2003, there was a sharp 
increase in chronic liver disease mortality rates overall 
and in both men and women; for men, the mortality rate 
increased from 14 per 100 000 to 35 per 100 000 population 
and for women, from 8 per 100 000 to 16 per 100 000 
population. Since 2003 the rates have decreased for both 
men and women. In 2014, chronic liver disease mortality 
rates were highest in people aged 55–64 years (36 per 
100 000 population).
Metric 5·6: hospital and community alcohol services
The most effective and cost-effective means to reduce 
alcohol-related deaths and hospital admissions is to 
reduce alcohol consumption in extreme and harmful 
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Figure 6: Trends in wholly attributable hospital admission episodes
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Figure 7: Trends in deaths directly attributable to alcohol and the affordability of various alcohol drinks as 
influenced by changes in alcohol duty (England and Wales)
All data normalised to 100% in 1980. Data from Health and Social Care Information Centre, June, 2015.62 
[A: reference renumbered in line with order in text]
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drinkers by increasing the price. We also need to detect 
and intervene earlier in liver disease. Once patients 
present with liver disease it is too late [A: for successful 
treatment?] in most cases, and there is little evidence 
that any therapeutic strategy improves survival, but we 
do know that the main determinant of long-term 
survival is whether the patient abstains from alcohol.72 
As a result, efforts have been made to integrate alcohol 
treatment services with liver units in acute trusts. Data 
obtained from Public Health England indicate that of 
192 district general hospitals in England, currently 
(2015–16 financial year) ten to 13 hospitals are known to 
have no service. [A: if these data are unpublished, please 
obtain Iain Armstrong’s written permission to cite] 
116 were known to have an alcohol service in March, 
2016; a further 42 were known to have services in 2014. 
So the total number of hospitals with services is 
probably between 116 and 158. Since 2014, six hospitals 
are known to have lost funding for their alcohol 
specialist services, while two have services that 
previously did not. Funding is generally a mixed 
economy from local authority public health and clinical 
commissioning groups or provider trusts, often in 
partnership. In December, 2015, a third of services were 
secure in their funding beyond 2018–19, nearly half 
were secure until at least 2018–19. However, a good deal 
of funding is short term; over a third were not assured 
of funding beyond the next financial year (2016–17) and 
20 had no funding identified for the coming financial 
year (2016–17).
There is concern that further local authority cuts will 
result in a substantial loss of alcohol services in England. 
This contrasts with Northern Ireland and Wales, where 
alcohol services are attracting substantial health board 
investment and are being developed. The Wales Liver 
Plan has made a firm commitment to develop ACTs 
[A: please spell out] embedded in secondary care with 
assertive outreach teams, a clinical lead has been 
appointed in three of the six health boards so far, and the 
number of alcohol specialist nurses has increased from 
13 to 17. In Northern Ireland, alcohol specialist nurses 
will increase from ten in 2013 to 18 in 2016, aiming for a 
total of 28 to ensure a 7-day alcohol specialist nurse 
service. In Scotland the current alcohol strategy is being 
refreshed and proposals for such teams are being 
considered.
The report Public Health post-2013,73 [A: reference added 
to list, subsequent references renumbered] published by 
the Commons Health Select Committee, shows how 
local authorities have undergone cuts to public health 
budgets year-on-year, after assuming responsibility from 
central government. The paper includes a survey 
commissioned by the Association for Directors of Public 
Health, which shows that local alcohol treatment services 
face the biggest public health cuts of all, with 46% of local 
authorities planning cuts to alcohol treatment services in 
2015–16, rising to 72% in 2016–17. The Commons 
Committee highlighted the government’s pledge to 
reduce health inequalities in the UK and that these cuts 
would undoubtedly increase inequalities. NHS England 
recommends that local authorities, clinical 
commissioning groups, and provider trusts should 
jointly fund alcohol services. Lack of agreement over 
funding responsibilities presents a major threat to the 
on-going provision of specialist hospital alcohol services 
and, as local authorities are forced to make further 
budget cuts, there is a danger that they will see these 
hospital-based services as an easier economy than 
services which have a more obvious effect on council 
outcomes.
Metric 5·7: survival of alcohol related liver disease 
admissions 
The NCEPOD report of 2013 identified a number of 
shortcomings in the hospital treatment of patients with 
alcohol related liver disease, and previous Lancet 
[A: correct?] Commission reports have outlined the 
variation in hospital mortality rates between trusts, with 
recommendations for more specialist liver units across the 
UK.48 However, there have been steady advances in the 
management of patients with alcohol-related liver disease, 
endoscopic banding of varices, terlipressin treatment of 
hepatorenal syndrome, and in intensive care.74-76 There 
have been steady year-on-year improvements in in-hospital 
mortality across acute trusts in the UK (figure 8). [A: 
“figure 8” correct here (not figure 4, as originally cited)?]
Baseline data for longer-term survival has been calculated 
using NHS data (2005–14) supplied by liver units in 
Southampton, Plymouth, Newcastle, and Sunderland 
(figure 9). 5-year survivals remain poor, varying from 
around 85% for viral hepatitis to 65% for alcohol-related 
liver disease and 35% for primary liver cancer.
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Figure 8: In-hospital mortality of liver disease for acute trusts in England
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One year survival metrics will be used to measure 
improvements in survival against the 2005–14 baseline 
(figure 6) [A: should this be figure 9?]. The very high 
1-year mortality of patients with alcohol-related, 
cryptogenic liver disease and primary liver cancer reflects 
the late diagnosis of the majority of liver cirrhosis.
Data from Scotland relating to metric 3: number of 
admissions from alcoholic liver disease
Figure 10 shows the trends in rates of hospital stays for 
four conditions; alcoholic liver disease, alcoholic liver 
failure, alcoholic acute hepatitis, and alcoholic cirrhosis. 
In 2014–15, there were 35 059 alcohol-related general 
acute hospital stays in Scotland; a standardised rate of 
672 stays per 100 000 population. This is a continuation 
of the fall in rates since 2007–08. However, in 2014–15, 
rates for hospital stay were still more than four times 
higher than at the beginning of the time trend. The 
decrease since 2007–08 has been predominantly driven 
by the reduction in more acute conditions, such as 
harmful use and toxic effect, whereas the more chronic 
conditions, such as alcohol-related liver disease, have 
increased. The increase in hospital stays seen up to 
2007–08 has been driven to a large extent by repeat visits 
rather than new patients being admitted to hospital. In 
2014–15, alcohol-related stays in general hospitals were 
nearly eight times more frequent for individuals living in 
the most deprived areas compared with the least deprived 
areas. The rate for alcoholic liver disease, 6963 stays in 
2014–15, has increased over the last two years and showed 
a much flatter curve in the previous years than for 
alcohol-related conditions overall. The breakdown of 
alcohol-related liver disease shows that most of the rise is 
due to cirrhosis and to repeat admissions, with the 
number of new patients being relatively static, suggesting 
that rather than a reduction in the number of patients 
developing alcohol-related cirrhosis, they are more likely 
to survive their first admission.
Recommendation 6: promotion of healthy 
lifestyles to reduce obesity and the burden of 
NAFLD
Metrics for recommendation 6 are shown in panel 8. 
Obesity and its effects on health, such as non-alcoholic 
fatty liver disease, continues to be a major burden to the 
UK that will require concerted efforts by government, 
health-care professions, and the public if it is to be 
addressed. This section will provide objective 
assessments of the prevalence of obesity in children and 
adults in the UK as well as data on the subsequent effects 
of obesity on liver disease.
Metric 6·1: prevalence of child and adult obesity
Data from HSE, along with that from equivalent surveys 
in Wales, Scotland, and Northern Ireland, show the scale 
of the problem affecting both adults and children 
(figure 11) [A: “figure 11” correct?]. Ongoing monitoring 
of these data will be an important guide to the current 
burden of obesity and provide a benchmark to assess the 
impact of strategies to reduce obesity over the long term.
Data on childhood obesity are not available from all of 
the UK at this stage. Collation of these data, along with 
cross-referencing with data from the National Child 
Measurement Programme (NCMP), will be important to 
build an accurate picture of childhood obesity.
Metric 6·2: adoption of Health Select Committee 
priorities for childhood obesity
The recent Health Select Committee report77 identified 
key overarching objectives to protect families from the 
pressures of unhealthy food marketing by changing the 
obesogenic environment; to enable individual choice by 
making healthy food choices and access to opportunities 
for physical activity easier; to inform families of the risks 
associated with poor diet and physical inactivity; and to 
support children and families to lose weight and 
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Figure 9: Kaplan-Meier survival plots (months) from the time of first liver admission of patients from 
Southampton, Plymouth, Newcastle, and Sunderland, admitted 2005–14
ICD=International Classification of Disease. [A: correct? Should this give a specific edition?]
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maintain a healthy weight. The government published 
its childhood obesity plan78 in 2016. Table 6 assesses the 
extent to which the plan meets recommendations from 
the Health Select Committee. Very few of the 
recommendations are addressed in the plan, and most of 
those that are rely on voluntary commitments from 
industry.
Metric 6·3: Prevalence of NAFLD/non-alcoholic 
steatohepatitis in secondary care
HES data provide information on patients admitted to 
hospital with NAFLD or non-alcoholic steatohepatitis 
(NASH) as a diagnosis. While these data will be 
influenced by greater coding of NAFLD or NASH, they 
do capture the increased morbidity and mortality of 
patients with NAFLD or NASH, providing information 
on the burden of NAFLD or NASH on hospital bed usage 
(figure 12). [A: ok to cite figure 12 here?]
At present there is substantial variation in the 
identification and referral of patients with NAFLD, 
reflecting the lack of clear guidance. A BSG-led 
[A: please spell out BSG] group with representation 
from the relevant stakeholders, including patient groups, 
will report in late 2016 with new guidance on the 
management of abnormal liver function tests. This 
should help standardise care, reduce unnecessary 
referrals, and ensure that patients needing further 
investigation are identified at the appropriate stage.
Metric 6·4: number and proportion of patients with 
NAFLD as a diagnosis assessed for liver transplantation
This metric provides information on the impact of 
obesity on inducing end-stage liver disease due to 
NAFLD, as well as providing a measure of the provision 
of adequate services for such patients with NAFLD or 
NASH.
Patients with NAFLD as a primary or contributory 
factor still account for a relatively small proportion of 
elective cases on the liver transplant waiting list 
(figure 13).[A: ok to cite figure 13 here?] This might reflect 
a low number of patients with end-stage liver disease due 
to NAFLD or challenges with identifying, referring, and 
listing such patients for transplantation. Further 
exploration of these data are required to ensure equity of 
access to transplantation for such patients, although the 
likelihood of them having more co-morbidities is a 
consideration.
Metric 6·5: number of bariatric surgery operations per 
100 000 population
This metric is a measure of the extent of service provision 
for those in clear need of further support and 
intervention. Referral to weight management services 
and consideration of bariatric intervention is strongly 
supported by an evidence base.
The current rate of service provision is much less than 
1% of those with a BMI of 40 kg/m2 or greater and more 
recent data from the Health and Social Services 
Information Centre indicate an almost 10% fall in the 
number of NHS bariatric surgery procedures (figure 14). 
19
97
–9
8
19
98
–9
9
19
99
–20
00
20
00
–0
1
20
01
–0
2
20
02
–0
3
20
03
–0
4
20
04
–0
5
20
05
–0
6
20
06
–0
7
20
08
–0
9
20
10
–11
20
07
–0
8
20
09
–10
20
11
–12
20
12
–13
20
14
–15
20
13
–14
0
50
100
150
200
250
EA
SR
 p
er
 1
00
 0
00
 p
op
ul
at
io
n
Year
Alcoholic liver disease, overall
Alcoholic liver disease, alcoholic hepatic
Alcoholic liver disease, acute hepatitis
Alcoholic liver disease, cirrhosis
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Panel 8: Metrics for recommendation 6
6·1 Prevalence of child and adult obesity
6·2 Adoption of Health Select Committee priorities for 
childhood obesity
6·3 Prevalence of NAFLD/non-alcoholic steatohepatitisin 
secondary care
6·4 Number and proportion of patients with NAFLD as a 
diagnosis assessed for liver transplantation
6·5 Number of bariatric surgery operations per 100 000 
population
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Notably, the rate of surgery in Sweden was 78 procedures 
per 100 000 population in 2013 (data from Scandinavian 
Obesity Surgery Register79). This would equate to a figure 
of 49 000 procedures per annum for the UK, which is 
more than six times the current rate of service provision. 
There is no justification for such a difference, especially 
when the higher rate of obesity in the UK is taken into 
account, testifying to the marked underprovision of 
bariatric surgery in the UK.
Recommendation 7: eradication of chronic HCV 
infection from the country by 2030 and a major 
reduction in the burden of disease for 
hepatitis B
The 2014 report of the Lancet Commission11 made a 
number of key recommendation for viral hepatitis, 
including eradication of infections from chronic hepatitis 
C virus in the UK by 2030 using antiviral drugs; reducing 
the burden of hepatitis B virus; targeting high-risk 
groups for these viruses, including immigrant 
communities; and use of a universal six-in-one 
vaccination for infants against hepatitis B. This report 
looks at metrics to measure progress towards these goals.
In May, 2016, 194 governments, including the UK, 
adopted WHO’s first ever Global Health Sector Strategy 
for Viral Hepatitis (GHSS) at the 69th annual World 
Government’s child obesity plan Traffic light 
assessment
Strong controls on price promotions of unhealthy food 
and drink
Not included Red
Tougher controls on marketing and advertising of 
unhealthy food and drink
Not included Red
A centrally led reformulation programme to reduce sugar 
in food and drink
Launch of a voluntary sugar reduction programme with aim of reducing 
overall sugar by at least 20% by 2020, including a 5% reduction in 
year 1. Not clear what fines or levies will be implemented if targets are not 
achieved.
Amber
A sugary drinks tax on full-sugar soft drinks, in order to 
help change behaviour, with all proceeds targeted to help 
children at greatest risk of obesity
A soft drinks industry levy will be introduced in England from 2018, with the 
revenue from it invested in programmes to reduce obesity and encourage 
physical activity and balanced diets for school age children.
Green
Labelling of single portions of products with added sugar 
to show sugar content in teaspoons
Establish a review of additional opportunities to go beyond current labelling 
scheme. Examples given include clearer visual labelling, such as teaspoons of 
sugar in packaged food and drink.
Amber
Improved education and information about diet Discussion of use of information technology such as the Change4Life Sugar 
Smart app. No further investment or new programme.
Red
Universal school food standards Funding generated from the sugar levy will be diverted towards the primary 
physical education and sport premium, which includes school healthy 
breakfast clubs. From September, 2017, a voluntary health rating scheme for 
primary schools will be taken into account during Ofsted inspections. The 
new school food standards will be updated in the light of refreshed 
government dietary recommendations. The majority of schools are subject to 
the school food standards. However, some academies and free schools are 
not. There will be a campaign by the Secretary of State for Education 
encouraging all schools to commit to the standards.
Amber
Greater powers for local authorities to tackle the 
environment leading to obesity
No change in local authority power. There will be further encouragement for 
local authorities to adopt the Government Buying Standards for Food and 
Catering Services (GBSF) standards, particularly in leisure centre vending 
machines. This will be accompanied by the full uptake of GBSF in central 
government Departments.
Red
Early intervention to offer help to families of children 
affected by obesity and further research into the most 
effective interventions.
Re-committing to the Healthy Start scheme, which provided an estimated 
£60 million worth of vouchers to families on low income across England in 
2015–16. These can be exchanged for fresh or frozen fruit or vegetables and 
milk. No other plans.
Red
Table 6: Measures in the government’s child obesity plan measured against recommendations of the Health Select Committee.
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Figure 12: Finished consultant episodes (FCE) in which NAFLD was a coded diagnosis in the UK, 1999–2014
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Health Assembly. The strategy sets a goal of eliminating 
hepatitis B and C by 2030 and includes prevention and 
treatment targets.80
The metrics shown in panel 9 were selected to align 
with both the Lancet Commission’s recommendation 
and the GHSS. The first four link with the ten core 
indicators for monitoring and evaluating HBV and 
HCV infection recommended in a recent WHO 
document81 [A: document added to reference list] and 
will facilitate comparisons with other countries and 
allow year by year monitoring of progress. According to 
the WHO report, the ten core indicators are: (1) 
prevalence, (2) infrastructure for testing, (3) vaccination 
coverage of newborns for HBV, (4) needle and syringe 
distribution, (5) facility level injection safety, (6) people 
diagnosed, (7) treatment coverage or initiation, (8) HCV 
cure and HBV suppression numbers, (9) incidence of 
new infection, and (10) attributable mortality and 
morbidity.
Metric 7·1: number of HCV-infected patients treated 
with new HCV direct-acting antivirals and number of 
patients achieving cure or SVR12 (linked with WHO 
indicator 8)
This metric allows a direct comparison of numbers cured 
with numbers of newly diagnosed HCV infections as an 
indicator of progress towards eradication and reduction 
in prevalence, and allows comparison of treatment 
numbers with other European countries and the impact 
of initiatives for testing and treating HCV.
Treatment numbers in the UK are rising (figure 15). [A: ok 
to cite fig 15 here?] As of August 22, 2016, in England, 
3482 patients with HCV have been started on treatment 
since April 1 (2·2% of the estimated 160 000 chronically 
infected cases),82 [A: reference was out of order; please check 
renumbering] with a target of 10 000 to be treated by the end 
of March, 2017 (6·3% of the prevalent population). The 
present focus of NHS England is on patients with advanced 
liver disease and plans to increase the proportion of patients 
on therapy year-on-year are dependent on an anticipated fall 
in drug costs as a consequence of increased competition. 
Despite the rise in therapy, eradication of HCV in England 
by 2030 is unachievable with these numbers, as it will take 
until 2032 to treat the known patient pool, without treating 
any new infections, and either a marked increase in funding 
or a reduction in the cost of treatment will be needed to 
achieve the goal of eradication. There are no new widespread 
testing programmes in place in England currently to 
increase diagnosis.
In Scotland in 2015, 1700 patients with HCV were 
treated, with similar numbers expected for 2016. This 
represents about 4·5% of the estimated 38 000 chronically 
infected cases (data from John Dillon). [A: please provide 
JD’s institution and his written permission to cite data] 
In Wales, central funding was provided from 2015–16 
with 464 patients treated and funding to treat 900 in 
2016–17 (data from Brendan Healy). [A: please provide 
BH’s institution and his written permission to cite data] 
This represents 7·5% of the estimated 12 000 chronically 
infected cases.
By comparison, in Australia (where the price of therapy 
is capped to allow unlimited access), 22 470 individuals 
were started on treatment from March to June, 2016; close 
to 10% of the total infected population of 230 000 in just 
4 months.83 In Germany (where expenditure on antiviral 
drugs is estimated to be five times greater than in England) 
numbers started on treatment [A: correct?] are estimated 
to be stable at 25 000 per year since 2015 [A: this is less 
than one year; please clarify], 10% annually of their 
estimated prevalent pool [A: this sentence is unclear; 
please rephrase] of 250 000.84 In Australia and Germany all 
of the known diagnosed HCV cases will be treated within 
a few years [A: please provide supporting reference for 
this broad statement] and there are plans for widespread 
testing programmes to diagnose the remaining cases.
Sustained viral response (SVR) rates for treatment 
initiated in 2016 are not yet known, but the earlier NHS 
England Early Access Programme for advanced liver 
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Figure 13: Proportion of adult elective NHS patients with NAFLD waiting for 
a liver transplant in the UK
NAFLD=patients with NAFLD as either a primary or secondary diagnosis. 
All=total number of patients [A: awaiting liver transplant?]. Data from January 
snapshot of liver transplant list, courtesy of Elisa Allen, NHS Blood and 
Transplant. [A: figure title and legend correct? Two titles were provided in 
the original file; this version combines them. Please provide written 
permission from Elisa Allen to cite her as a source]
Figure 14: HES data on finished consultant episodes (FCE) for patients 
admitted for bariatric surgery [A: please spell out FCE]
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disease, which treated 467 patients (409 with 
decompensated cirrhossi), achieved an overall SVR rate 
of 81·6% (381/467). For genotype 1 infection, SVR was 
90·5% (209/231) and 68·8% for genotype 3 (132/192).80
Metric 7·2: number of patients diagnosed with HCV and 
HBV (linked with WHO indicators 2 and 6)
In England and Wales there were 11 626 laboratory reports 
of newly diagnosed HCV infection in 2015 (11 997 in 2014) 
(table 7). Some of these will be recent infections and others 
previously undiagnosed long standing chronic HCV. This 
is greater than the number of patients being treated.
Nearly all new cases of HCV infection arise in people 
who inject drugs, with incidence remaining relatively 
stable (eight per 100 person-years in 2015 and seven per 
100 person-years in 2011). The prevalence of HCV in 
people who inject drugs also shows no sign of reducing, 
with around 25% of these drug users being HCV 
antibody positive within 3 years of first injecting 
(figure 16).
For 2015, a total of 457 cases of acute or probable acute 
HBV infection were reported—an annual incidence of 
0·83 per 100 000 population per year.82 [A: correct reference?]
Metric 7·3: mortality from HCV and HBV—number of 
HCV or HBV associated hepatocellular carcinomas, 
number of transplants for HCV or HBV, and HES data for 
bed days associated with HCV and HBV infection (linked 
to WHO indicator 10)
The PHE annual report on Hepatitis C in the UK for 
2016 presents a new evaluation of HES data that allows 
estimation of the number of new cases of end-stage liver 
disease or hepatocellular carcinoma arising as a 
consequence of HCV infection. There are some 
limitations due to variations in datasets between UK 
countries. However, these show a fairly constant number 
of approximately 1800 new cases each year since 2010 
(figure 17). [A: ok to cite here?]
Between 2005 and 2014, annual deaths from 
HCV-related end-stage liver disease and hepatocellular 
carcinoma in the UK rose from 215 to 457 (figure 18). 
[A: ok to cite here?] Although 2015 data are preliminary 
and should be interpreted with caution, it is encouraging 
to see an observed fall in mortality of 11%. This fall might 
be the result of new direct-acting antiviral drugs 
introduced from 2014–15, particularly for those 
individuals with advanced disease.
In the year to March 2015, 119 (19% of total) 
HCV-infected adult patients underwent an elective liver 
transplantation; in 2014 the number was 133 (21%).
Metric 7·4: numbers of infants starting and numbers 
completing a course of HBV vaccination (linked to WHO 
indicator 3)
PHE reports vaccine coverage data in England for three 
doses of hepatitis B vaccine in infants born to mothers 
positive for hepatitis B surface antigen (HBsAg) who 
reached the age of 1 year in this quarter (ie, those born 
between January and March, 2015), and coverage of four 
doses of vaccine in infants who reached two years of age 
(those born between January and March, 2014). The 
2015 data shows 86% vaccine completion (1699 of 
1987 infants) at 12 months and 74% completion (1681 of 
2275) at 24 months. For the first quarter of 2016, the 
12 and 24 month returns (data from 127 and 122 of 
151 former primary care trusts, respectively) show that 
91% of 481 infants received three doses of vaccine by 
12 months and 69% of 495 infants received all four 
doses by 24 months.
Panel 9: Metrics for recommendation 7
7·1 Number of HCV-infected patients treated with new HCV 
direct-acting antivirals and number of patients achieving cure 
or SVR12
7·2 Number of patients diagnosed with HCV and HBV
7·3 Mortality from HCV and HBV:  number of hepatocellular 
carcinomas associated with HCV or HBV, number of 
transplants for HCV or HBV, and HES data for bed days 
associated with HCV and HBV infection
7·4 Numbers of infants starting and numbers completing a 
course of HBV vaccination
7·5 Universal HBV vaccination offered by region (yes or no)
SVR12=sustained virus response at 12 weeks. [A:  ok?]
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Figure 15: Numbers of patients treated for hepatitis C in the UK 82
Data from Scotland available by financial year were grouped with data by calendar year for other UK countries—
eg, 2011–12 grouped with 2011. Data for Wales not available for 2007–10 and data for one [A: Welsh?] health 
board missing in 2014. Data for England for 2015 are provisional estimates for the 12-month period 
June, 2015–April, 2016, based on clinician-reported intention to treat where there is some robustness about 
intention to treat (eg, incomplete or other records excluded). [A: unclear, please clarify] Method of data collection 
changed in Wales in 2015 and these data [A: ie data for Wales for this year?] are provisional.Sources: Regional 
Hepatology Unit, Belfast Trust for Northern Ireland; Health Protection Scotland, using data supplied by hepatitis C 
treatment centres; Public Health Wales, using data from health boards; NHS England for 2015 provisional estimate 
for England; sentinel surveillance of hepatitis bloodbourne virus testing for sampled estimates for 2012–14 for 
England; estimates from Roche sales, IMS supply chain manager, and Pharmex data for England for 2007–11. 
[A: figure legend could not be copied from the image provided so it has been retyped, please check. Please 
confirm that you have obtained formal permission to reproduce (from PHE?)]
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Metric 7·5: has universal vaccination for HBV been 
introduced (yes or no)
At the time of writing, the UK government has accepted 
universal immunisation for hepatitis B but this has not 
been introduced.
Recommendation 8: Increasing awareness of 
liver disease in the general population, within 
the NHS, and, vitally, with governments; 
increasing the inclusion and involvement of 
liver patients and patient groups in new 
developments and ongoing work with national 
and local initiatives
Metric 8·1: government supported national liver plans
Panel 10 shows the metrics for recommendation 8. The 
initial Lancet Commission on Liver Disease’s report 
highlighted that the increasing burden of liver disease in 
the UK was getting worse and that liver disease is the 
third most common cause of premature death, with a 
400% increase since 1970 and a trajectory that continues 
to climb. In order to decrease this and improve care, 
treatment, and support for those with and affected by 
liver disease, national liver plans must be developed to 
outline clearly government supported actions; and 
improvements for liver health, from prevention through 
to cure, long--term support, and end-of-life care, must 
include liver health issues for children and adults. [A: 
previous sentence was slightly unclear - please confirm 
that the edited version retains your intended meaning] 
To support the national liver plan, a multidisciplinary 
implementation committee, with patient representation, 
should be formed to deliver and monitor its success. 
Additionally, to support the clinical elements of the plan’s 
recommendations, a national clinical director for liver 
health must be appointed to lead on the improvements 
needed. [A: table has been removed and incorporated 
into the text] England, Northern Ireland, and Scotland 
have not yet published a national liver plan. In Wales, 
Together for Health—Liver Disease Delivery Plan was 
published in May, 2015,4 an implementation committee 
[A: has been, or is being?] developed with patient 
representation, and Andrew Yeoman was appointed as 
national clinical director in 2016. The recommendations 
are already having a positive effect in Wales and provide a 
benchmark for other countries.
Metric 8·2: Geographical variation in liver disease 
mortality: Public Health England local authority liver 
disease profiles
Variations in mortality rate from liver disease persist 
between local authorities in England with a four-fold 
variation in mortality rates for men and women—
variation is 3·8 for men (52 per 100 000 in Blackpool 
compared with 13.7 per 100 000 in Buckinghamshire) and 
4·3 for women ( 28 per 100 000 in Blackpool compared 
with 6.6 for 100 000 in Barnet). The variation is even 
more stark when years of life lost under age 75 years are 
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Figure 16: Estimated UK-wide prevalence of antibodies to hepatitis C among 
people who began injecting drugs in the previous three years, 2008–15
This figure uses data from two ongoing survey programmes that together cover 
the whole of the UK. Data from these surveys have been weighted by size of 
adult (age 16–64 years) population and then combined. The survey covering 
Scotland is not annual, so data are presented only for years where both surveys 
were done. Value for 2015 weighting is based on 2014 mid-population 
estimates. [A: please clarify, what is mid-population?] Sources: Needle 
Exchange Surveillance Initiative [A: ok?], University of West of Scotland and 
Health Protection Scotland; Unlinked Anonymous Monitoring survey of people 
who inject psychoactive drugs by Public Health England with assistance from 
Public Health Wales and Public Health Agency Northern Ireland. [A: please check 
retyped figure legend and confirm that you have obtained formal 
permission to reproduce (from PHE?)]
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
East Midlands 259 402 588 576 515 673 672 549 591 401
East of England 684 695 794 706 607 844 776 707 792 840
London 1190 1017 966 856 968 2012 2789 3089 3836 4091
North East 245 141 167 275 317 310 301 360 305 233
North West 1380 1737 1666 2117 1807 1514 1797 1981 1496 1385
South East 379 786 1083 1147 1170 1300 1298 1137 1323 1331
South West 872 1046 1114 999 732 973 1111 997 983 1077
West Midlands 487 614 673 860 778 774 740 781 648 864
Yorkshire and Humber 1449 1363 1344 1091 981 1507 1376 1470 1513 1326
Wales 327 333 487 356 318 486 502 690 510 78
Total 7272 8134 8882 8983 8193 10 393 11 362 11 761 11 997 11 626**
Table 7: Laboratory reports of hepatitis C by region (Public Health England Centre), England and Wales (2006–015)85 [A: cited report added to reference list, please check]
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compared, with a variation of 8·4 (89·3 years of life lost 
per 10 000 in Blackpool compared with 10·5 per 10 000 in 
Rutland). These variations reflect both variation in risk 
factors and variation in access to NHS Services. PHE will 
publish an updated Atlas of Variation in Liver Disease.
The Lancet [A: correct?] Commission recommends that 
all UK [A: correct?] countries develop local liver health 
profiles and use them to address inequalities and 
priorities i with annual updates to evaluate success. At 
present, of the countries in the UK, only England has 
published a local liver health profile. [A: we have replaced 
table 10 with this sentence in order to save space – please 
confirm that the wording is ok].
Metric 8·3: inclusion and involvement of patient and 
patient support groups
To best address the holistic needs of patients it is vital to 
have their involvement in developments, service design, 
governance, and so on. There is still a need to ensure this 
involvement happens and all health officials and 
clinicians should advocate for this input when it is not 
present. In the Liver QuEST52 project to support the 
improvement of hospital liver services, the peer review 
teams include patients but only a few DGHs have been 
visited.
The 22 Hepatitis C Operational Delivery Networks in 
England aim to have patient involvement throughout as 
soon as possible with the help and support of the 
Hepatitis C Trust. This involvement has not yet been 
audited [A: end of section amended as outlined in 
response to reviewers – please confirm that edited 
wording is correct]
Metric 8·4: public health sponsored public awareness 
campaigns for obesity and alcohol
To raise public awareness campaigns about the two main 
causes of liver disease, alcohol and obesity, must be 
developed and promoted effectively to ensure that the 
public is as informed as possible and empowered to make 
improvements to their lifestyle. Frequently updated 
national campaigns are vital to reverse the increasing 
burden of preventable liver disease. In assessing the value 
of these campaigns, cohorts will need to be studied for the 
effect on their lifestyle, body weight, and alcohol 
consumption, which are relatively easy measures to follow. 
[A: sentence added from response to reviewers– ok?]
Examples of government-funded national campaigns 
are shown in the appendix. [A: we are unable to include 
links in tables, so we would like to include this table as a 
web appendix – this way the links can remain in the table 
and readers can click straight through] Additionally, 
many charities, including Alcohol Concern, Cancer 
Research UK, Diabetes UK, and the British Liver Trust, 
have national campaigns that highlight the detrimental 
effects of obesity and alcohol on health.
General policy strategy in the devolved nations 
Scotland
[A: It is unusual to give individual contributing authors’ 
names in the text, so I have deleted them in the following 
sections – if you would like to specify which authors were 
responsible for specific sections, please give these details 
in the Contributor’s statement.] Alcohol use, obesity, and 
hepatitis C are more prevalent in Scotland than in the 
rest of the UK (figure 19). [A: ok to cite fig 19 here?] As in 
For Liver disease profiles in 
England see http://fingertips.
phe.org.uk/profile/liver-disease.
See Online for appendix
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Figure 18: Deaths from end-stage liver disease or hepatocellular carcinoma in 
people with hepatitis C mentioned on the death certificate in the UK, 2005–15
ESLD defined by codes or text entries for ascites, bleeding oesophageal varices, 
hepatorenal syndrome, hepatic encephalopathy, or hepatic failure. 2015 data 
provisional for England and Wales and missing for Northern Ireland. Sources: 
Office for National Statistics for (England and Wales); deaths registration data 
from Northern Ireland Statistics and Research Agency (Northern Ireland); Health 
Protection Scotland in association with the Information Services Division 
(Scotland). [A: please check retyped figure legend and confirm that you have 
obtained formal permission to reproduce (from PHE?)]
0
2010 2011
Year
2012 2013 2014 2015
2500
2000
1500
1000
500
In
cid
en
ce
 o
f H
CV
-r
el
at
ed
 E
SL
D/
H
CC
Figure 17: Preliminary estimates of incidence of HCV-related end-stage liver 
disease (ESLD) or hepatocellular carcinoma (HCC) in the UK, 2010–15
An episode of ESLD or HCC is defined as the first if there have been no previous 
episodes of ESLD or HCC for that individual in the previous 5 years (0·4% in England 
estimated to have had an episode >5 years earlier). ESLD defined by codes or text 
entries for ascites, bleeding oesophageal varices, hepatorenal syndrome, hepatic 
encephalopathy, or hepatic failure. 2015 data provisional for Wales and missing for 
Northern Ireland. In England, about 1·5% of individuals admitted had identifiers 
missing in HES (2010–14) and were allocated new HES identifiers; any previous 
episodes of ESLD for these individuals would not be linked. Sources: HES, Health 
and Social Care Information Centre (England); Hospital Inpatient System 
(Northern Ireland); Patient Episode Database for Wales, NHS Wales Informatics 
Service (Wales); Health Protection Scotland in association with the Information 
Services Division (Scotland). [A: please check retyped figure legend and confirm 
that you have obtained formal permission to reproduce (from PHE?)]
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the rest of the UK, the natural history of liver disease is of 
late presentation with decompensated liver disease or 
hepatocellular carcinoma, with a pressing need to 
develop strategies for earlier detection and more effective 
intervention. Scotland does not have an integrated liver 
plan but has a series of activities that cover the major 
causes and management of liver disease. These include 
an alcohol strategy, the sexual health and blood borne 
virus framework, and a department of health initiative to 
improve management of outpatients, the National 
Delivering Outpatient Integration Together (DO IT) 
Programme, with a workstream focussed on abnormal 
liver function tests.
The current Scottish alcohol strategy is undergoing 
review to add to and adjust existing policies in the light of 
experience with the strategy. Scottish Health Action on 
Alcohol Problems (SHAAP) with the support of the 
Scottish Government has brought together a working 
group to focus the strategy on alcohol-related liver 
disease, a major driver for mortality and costs. The main 
recommendations are for an assessment of liver fibrosis 
in all those presenting with alcohol excess [A: for clarity, 
please define alcohol excess] and prioritisation of those 
with evidence of advancing fibrosis in alcohol treatment. 
The group will recommend that people admitted to 
hospital with the consequences of alcohol-related liver 
disease receive standardised management in accordance 
with the BSG/BASL [A: please spell out] care bundle and 
have follow-up treatment plans with alcohol services in 
place before discharge. How these interventions will be 
delivered is under consideration.
The existing alcohol strategy has had substantial effects 
on reducing alcohol-related mortality. In 2015, there were 
1150 directly alcohol-related deaths (defined largely by 
alcohol-related liver disease), the third lowest annual 
total since 1997, compared with the peak of 1546 in 2006 
(figure 20). It is speculated that the fall is secondary to 
the increases in the price of alcohol due to the economic 
downturn and policies banning alcohol multibuy 
promotions, which were not subject to legal challenge. 
This trend provides further indirect evidence that price is 
a key lever for change in alcohol-related mortality. 
Minimum unit pricing could have an even greater 
impact; it remains under judiciary review.
At the World Hepatitis summit [A: please add year (and 
month, if in 2016)] the Scottish Government signed the 
Glasgow Declaration committing to the elimination of 
HCV, and it remains committed to removing HCV as a 
substantial public health issue in Scotland. The 
government has committed to reduce HCV-related liver 
failure and hepatocellular carcinoma by 75% by 2020 
from 2015 levels. HCV treatment targets have been 
exceeded, and with increased HCV prevention activity, 
have been associated with year-on-year falls in the 
prevalence of HCV. There is also early evidence of a fall 
in the numbers of patients presenting with HCV-related 
liver failure.
The management of abnormal liver function tests 
continues to be a major challenge, with many patients 
not being investigated and only 1·4% converting [A: 
progressing? Or leading to?] into a diagnosis of liver 
disease in some series [A: reference?]. The DO IT 
programme ensures all patients with clinically significant 
liver disease are investigated, while limiting investigation 
of non-significant abnormalities of liver function tests [A: 
how does it do this?]. A pilot project currently nearing 
completion is using a minimal set of diagnostic criteria 
for liver diseases combined with automatic cascading of 
liver screen investigations on the original sample when 
first discovered to be abnormal. [A: please rephrase this 
sentence to clarify the meaning] Preliminary results 
suggest that this process assigns a diagnosis of liver 
disease [A: do you know that this process assigns the 
correct diagnosis to these patients? How are these 
minimal diagnostic criteria validated or evaluated?] to 
more than 50% of patients on the basis of the liver screen 
and aetiological information [A: what do you mean by 
“aetiological information”?].
Wales
[A: as above, A Yeoman’s name deleted] In 2015, the 
Welsh Government launched a national strategy,4 [A: 
reference added] to tackle the rise in morbidity and 
mortality related to liver disease in Wales (which has 
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Figure 19: Deaths from chronic liver disease in Scotland, by condition [A: please confirm that figure title is correct]
EASR=European age-standardised rate
Panel 10: Metrics for recommendation 8
10·1 Government supported national liver plans
10·2 Regional variation in PHE health profiles
10·3 Inclusion and involvement of patient and patient 
support groups
10·4 PH [A: PHE?] sponsored campaigns in obesity and alcohol
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mirrored that seen across the UK), the culmination of a 
collaboration between Public Health Wales, the Welsh 
Association of Gastroenterology and Endoscopy (WAGE), 
and key stakeholders, with an annual budget of £1 million 
from the Welsh Government.
The plan aims to improve activity across six key areas: 
prevention, early detection, fast and effective care, living 
with liver disease, improving information, and targeting 
research, each area with major objectives and metrics. 
Specific subgroups formed to date include the blood 
borne virus, early detection, and clinical services 
subgroups. A national clinical lead (0·2 whole time 
equivalent) has been appointed and a full-time 
administrator will support the delivery of objectives 
determined by the implementation group.
There have already been areas of substantial progress 
in the care of patients with liver disease in Wales. The 
Wales blood borne virus network, consisting of 
representatives from each of the six health boards in 
Wales and an external advisor, David Mutimer from the 
Birmingham Liver Unit, supported by an excellent, 
established network of specialist nurses, set criteria [A: 
please clarify what the criteria are for-referral to specialist 
treatment centres?] (Fibroscan [A: we avoid use of trade 
names – can this be changed to transient elastography?] 
>9·5 kPa or other urgent need for therapy) and set up a 
panel to discuss patients for appropriateness if discordant 
[A: please clarify: appropriate for…., and discordant 
from….] or with extenuating circumstances to ensure 
equitable access to new therapies across Wales.
This approach was supported by central government 
funding and, for the financial year 2015–16, delivered 
directly active antiviral therapy to 464 patients in Wales, 
most with cirrhosis or advanced fibrosis. For 2016–17, 
further funding has been agreed to treat approximately 
900 patients, and the access criteria relaxed 
(Fibroscan 6 kPa [A: as above]). Treatment of this number 
of people on a recurrent basis should lead to a reduction 
in the population prevalence of the disease.
The network has also developed industry partnerships 
that have led to specific initiatives around diagnosis and 
provision of treatment to groups such as prisoners or 
people who inject drugs.
The Wales Harm Reduction Database has been 
awarded funding agreed through the liver plan to create a 
blood borne virus module that will cover the initial 
screening, consent and testing, diagnosis, and referral to 
specialist treatment services for patients who might have 
hepatitis B, hepatitis C, or HIV. It is expected that the 
module will be fully implemented, following training 
across Wales, early in 2017. A blood borne virus specific 
electronic clinical management system is also in 
development. Liver plan funding has also been allocated 
to the development of point of care testing in viral 
hepatitis.
The development of alcohol care teams based in 
secondary care was a key early priority identified in 
relation to liver disease in Wales [A: sentence edited for 
clarity, please confirm that the wording is correct]. Such 
services had previously been patchy or nonexistent. The 
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Figure 20: Alcohol-related deaths registered in Scotland, 1979–2015, showing probable range of values around 5-year moving average [A: please clarify 
meaning of ‘moving average’ and how probable range is determined]
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plan has supported health boards to develop their own 
regional plans for alcohol care teams, ensuring that 
alcohol misuse becomes an organisational priority in 
their integrated medium-term plans, with £1 million 
allocated over a 2-year period to pump-prime the 
development of alcohol care teams in each health board 
in Wales. To date, four health boards have had funding 
approved for this purpose, with the plans for the 
remaining two in an advanced stage of development.
Regarding the early diagnosis of liver disease and 
improvement of links with primary care, a pilot is 
currently running in one health board to ascertain the 
usefulness of reflexly [A: do you mean ‘routinely’?] 
measuring aspartate transferase (AST) when alanine 
transaminase (ALT) is found to be elevated, so enabling 
calculation of the AST:ALT ratio, which the Lancet 
Commission had the potential to earlier identify patients 
with advanced fibrosis or cirrhosis (with those with a 
ration of >1 being referred for further assessment).
Given that the majority of patients with cirrhosis are 
diagnosed at the time of an admission with 
decompensation, it is hoped that this work will both lead 
to an earlier diagnosis of cirrhosis and avoid the need for 
the patient to return for another blood test. This approach 
has the potential to reduce GP workload (via reduced 
patient recall) and to reinforce the knowledge that 
minimal elevations of ALT can be associated with serious 
disease. This work will also help in the planned 
development of an all-Wales pathway for the management 
of abnormal liver function tests. A collaboration to 
improve public and patient knowledge of the risks of and 
care of liver disease is being developed alongside mature 
patient and carer support groups across Wales, which are 
also exploring wellness services that might link lifestyle 
factors recorded in such consultations [A: consultations 
in primary care?] with risks of liver disease. Work is 
being undertaken to improve access to liver 
transplantation for patient in Wales via the establishment 
of stronger regional networks and outreach clinics with 
transplant physicians.
Northern Ireland
[A: as above, author name deleted and section reworded 
to avoid single-author delivery] Northern Ireland is well 
behind England with respect to screening for early liver 
disease in the community, partly because of the different 
structures [A: of the health service?].The NICE guidance 
on hepatitis B has not yet been fully implemented, owing 
to the resource implications of Fibroscan) [A: ok to 
change to transient elastography? Please explain the 
resource implications briefly or reword].
With respect to provision of services 
(recommendation 3), Northern Ireland has a single 
regional liver unit in Belfast. No other hospitals have 
more than 2 hepatologists, although most of the nine 
hospitals outside Belfast have one gastroenterologist 
with an interest in liver health. This represents an 
improvement over the past 5 years, owing to recent 
appointments.
Northern Ireland is well served by the special 
arrangement with King’s College Hospital in London [A: 
addition of ‘in London’ correct?], which functions as an 
outreach centre for specialist paediatric services and 
continuity of care in transition to adult services, with 
weekly meetings via video conference to the King’s 
orthotopic liver transplantation listing meeting and a 
joint King’s–Belfast clinic every 2 months. Northern 
Ireland is the single biggest referrer of patients to King’s. 
The 2015 data [A: reference?] showed the highest 
number of patients listed for transplantation [A: ‘for 
transplantation’ correct?] per head of population 
(excluding the Isle of Man) although numbers fell back 
into the main stream, with 20–24 transplants per year. 
Survival data on 255 patients who had transplants up to 
2012 (90·9% 1-year survival, 80·2% 5yr survival, EASL 
[A: please define EASL] 2014) showed that shared care 
arrangement deliver outstanding results [A: reference?].
Paediatric liver transplant work is done through 
Birmingham [A: in a particular hospital/centre?] by 
historical arrangement. To facilitate transition to adult 
services, hepatologists from Northern Ireland join those 
from Birmingham in seeing adolescent patients over 
1–2 years at the paediatric clinic before they transition to 
the adult transplant service for follow-up. [A: please 
check that edited version is correct]
Northern Ireland is making excellent progress on 
alcohol care services and the Chief Medical Officer, 
Michael McBride, has been a strong supporter of this 
work. Data on the number of specialist nurses and 
alcohol care teams is covered in recommendations 2 and 
5. Three consultant led alcohol care teams have been 
established in Northern Ireland, in Belfast and in two of 
the other four Trusts (personal communication Roger 
McCorry, Belfast Trust Alcohol Care Team [A: please 
provide consent to cite McCorry]). A regional alcohol 
care-pathway has also recently been completed to 
standardise alcohol screening and care across the 
province.
Northern Ireland has an excellent HCV treatment 
programme that is able to provide all NICE-approved 
treatments for patients in Northern Ireland. There is a 
single virology laboratory so that all results go through 
one centre and all treatment is delivered through the 
Regional Liver Unit in Belfast. There is also a hepatitis 
network for Northern Ireland—a collaborative effort 
between public health and ourselves [A: by ‘ourselves’ do 
you mean hepatologists?] that helps to address the wide 
range of issues with viral hepatitis, including screening, 
prevention, and treatment pathways.
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